



The effects of 





Luis Figueiredo de Sousa 
 
A thesis submitted to the De Montfort University for the degree 
of Master of Philosophy 
 
Faculty of Life Sciences 
De Montfort University 
 
Haemostasis Department 







This thesis is the result of my own work and includes nothing which is the outcome of 








I want to express my gratitude to my supervisors Dr Roger Luddington and Prof Paul 
Whiting for their support and guidance throughout the project and for their assistance 
with refining the finished document; Dr Vilas Navapurkar for providing samples from 
the Addenbrooke’s Hospital ICU; Nazia Hussein for her Hepzyme data; Dr Martin 
Besser for the statistical advice and to the Department of Haematology, for its 
permission to carry out this research. 
I would like to specially thank my partner and friend Andrea; without her help, 
unconditional support, encouragement and long days on the computer I could not 
have finished this MPhil…Muchas gracias, Jusp! 
 
Finally I would like to dedicate this Thesis to our gorgeous and beloved son, Oliver 
(Super Nené) and also to our future little girl Carlota. 
 
III ABSTRACT 
Hypothermia and acidosis are often seen in trauma patients and the critically ill. Both 
significantly contribute towards the pathology of these conditions. These patients are 
often investigated for coagulopathy, often as a result of bleeding. Traditionally 
routine coagulation screening is performed in buffered systems at 37°C. Therefore 
the information returned by the laboratory tells the clinician what the clotting will be 
like if the hypothermia and acidosis are corrected. This is useful clinical information 
but does not accurately reflect the clinical situation at the time. 
Blood was taken from 40 consenting healthy adults and 17 critically ill patients to 
examine the effects of hypothermia and acidosis upon “normal” clotting. The 
STart®4 coagulometer was used to assess the prothrombin time (PT) and the 
activated partial thromboplastin time (APTT), the ROTEM® analyzer to assess 
thromboelastometry and the Fluoroscan Ascent to assess thrombin generation using 
calibrated automated thrombography (CAT). 
The results show a difference in interpretation between assays using fibrin 
polymerisation as an end-point as opposed to the generation of thrombin. The 
results of the CAT assay under hypothermic and/or acidotic conditions suggest that 
in spite of having initially a delayed lag time (lag time at 37°C = 7.91 min; lag time at 
31°C = 8.37 min (Table 4.3.)), once the thrombin burst occurs it will generate more 
thrombin which will increase the overall ETP (ETP at 37°C = 1777nmol of thrombin; 
ETP at 31°C = 2681nmol of thrombin (Table 4.3.)). Therefore a thrombotic profile 
may be seen instead of a bleeding tendency. 
In general, it seems that both parameters (lag time and ETP) are affected by both 
hypothermic and acidotic conditions on their own but when combining both of them 
together (hypothermia + acidosis) there was a cumulative effect which exaggerates 
the changes even more (lag time at 37°C/ pH 7.35 =.7.91min; lag time at 31°C/ pH 
6.9 =.10.46min. and ETP at 37°C/ pH 7.35 =.1777nmol of thrombin; ETP at 31°C/ pH 
6.9 =.2852 nmol of thrombin (Table 4.3.)). 
These particular observations have not been observed previously in any published 
literature to date, where a hypocoagulable coagulopathy is described under 
abnormal conditions, such as hypothermia and acidosis.  
 
IV ABSTRACT 
Although these standard clotting tests are performed at 37°C and physiological pH, in 
vitro testing of any given sample should ideally be performed at the patient’s own 
body temperature and pH as well as under the corrected conditions. This will give a 
picture of what is happening now compared to what will happen when the 
hypothermia/acidosis is corrected. 
It is possible that global assays of haemostasis may offer some insight into the 
pathology of hypothermia and acidosis. However, as always in science many more 
questions are raised than are answered. 
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Haemostasis is the complex mechanism of blood clotting and the ability to 
dissolve the clot after the damaged tissue has been repaired. This system 
allows the body can to control blood loss when vascular injury occurs. 
Haemostasis involves several reactions which require enzymes and tissues, 
such as coagulation factors, platelets, endothelial cells, fibrinolytic proteins, 
collagen and subendothelial microfibrils.  
 
First event when a vessel is damaged is vascular constriction. This will restrict 
the amount of blood that gets to the area of injury.  
With some internal endothelium lost, the anticoagulant action of the 
endothelial cells is interrupted. Now collagen and subendothelial microfibrils 
are in contact with the blood components. Platelets, which circulate close to 
the vessel wall will locate and adhere to the injury site. 
 After platelet adhesion has commenced, platelet activation will follow. 
Activated platelets change shape and release their granule contents 
(thromboxane A2, calcium, epinephrine, ADP and several coagulation factors). 
Activated platelets attract and activate other platelets and with the help of 
fibrinogen platelet aggregation starts to form a platelet plug.  
At this stage, the polymerisation of fibrinogen to fibrin will form a mesh that 
transforms an unstable platelet plug in to solid clot.    
When the vessel is finally repaired the clot is dissolved trough the fibrinolytic 
pathway, where plasmin plays the main role. Once the clot is removed blood 




2 CHAPTER I: INTRODUCTION 
1.1.1. Coagulation cascade 
 
At the site of injury the subendothelial tissues will be exposed and initiate the 
coagulation cascade (Fig. 1.1). Tissue Factor (TF) activates factor VII (VIIa), 
which will activate Factor IX (FIXa) and and also factor X into factor Xa 




















        
FXa helps to catalyze the conversion of prothrombin into thrombin.(Bode et 
al., 2006) thrombin is the main protein in the coagulation cascade; once 
thrombin is in the plasma the coagulation cascade changes dramatically. 






3 CHAPTER I: INTRODUCTION 
For example, it will work as an agonist to further activate platelets via a 
membrane platelet receptor: the Protease-activated receptor (PAR). Further 
stimulation of coagulation occurs as a result of back activation of factors by 
Thrombin. The back activation of factor XI (FXI) results in more generation of 
FIXa.  
The simultaneous activation of the cofactor FVIII allows the formation of the 






















Activation of another cofactor FV results in formation of the Prothrombinase 
complex (Swords et al., 1993) which results in an increase in thrombin 






4 CHAPTER I: INTRODUCTION 
The coagulation cascade is a complex process to ultimately form fibrin 
strands (Fig.1.3). 
These fibrin strands form a mesh along with aggregated platelets and trapped 
red cells at the site of vascular injury to form a clot. 
 
 
Finally, the clot firmness and stability is achieved by the action of activated 
























5 CHAPTER I: INTRODUCTION 
1.1.2. Fibrinolysis 
 
To maintain blood flow and prevent venous occlusion soon after the clot is 
formed and the vessel repair is underway. The mechanism to dissolve the clot 
is initiated. This process is known as fibrinolysis. 
 
 
During thrombus formation Tissue Plasminogen Activator (TPA) binds to 
polymerized Fibrin. This activates bound plasminogen molecules to produce 
Plasmin.  
 
Through a systematic hydrolytic digestive process plasmin will digest 
polymerized fibrin strands to ultimately dissolve the clot and restore blood flow 
(Zorio et al., 2008). 
 
Other proteins involved in the fibrinolytic pathway include: plasminogen, 
plasminogen activator inhibitor-1, tissue plasminogen activator, α2-






Plasminogen is a 90 kDa protein made by the liver. It is a single chain protein 
with six structural domains, five kringle domains and a protease domain, each 
with different properties. During fibrin polymerization plasminogen binds to 
fibrin via the Kringle domains (Fig. 1.4). 
 
Plasminogen activation requires plasminogen activators such as tissue 
plasminogen activator and urokinase plasminogen activator (t-PA, u-PA) 
which finally convert it into plasmin (Waisman 2002). 
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Figure 1.4. Plasminogen molecular structure (Picture taken from: 
http://www.chem.cmu.edu/groups/llinas/res/structure/hpk.html) 
 
1.1.2.2. Tissue plasminogen activator (TPA) 
 
TPA is the main activator of plasminogen. Made and secreted by the 
endothelial cells. TPA levels can increase with exercise, alcohol consumption 
or even drugs, like desmopressin acetate (DDAVP) (Girolami et al., 1995). 
Deep vein thrombosis risk is higher on people whose TPA levels do not 
increase with any of these stimuli. (Sue-Ling et al., 1987). 
 
TPA binds to fibrin by covalent bonds on its two kringle regions. TPA occurs 
principally as a complex together with its main inhibitor PAI-1. Plasmin 
changes a single-chain TPA into a double-chain molecule. When a clot is 
formed the fibrin in it will help TPA with binding and orientation to be able to 
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1.1.2.3. Urokinase  
 
Urokinase is a plasmin activator secreted by the urinary tract epithelial cells. It 
is present in small amounts in plasma and becomes attached to polymerized 
Fibrin, along with TPA at the time of clot formation. The molecule has only 
one single Kringle region which binds Fibrin. 
 
 
1.1.2.4. Plasminogen activator inhibitor-1 
 
The fibrinolytic process needs to be controlled by the body otherwise an 
increased destruction of fibrin could lead to big risk of bleeding. The main 
inhibitor of fibrinolysis is plasminogen activator inhibitor-1 (PAI-1) by stopping 
the action of TPA and/or urokinase. PAI-1 is made and secreted by the 




Plasmin, like Thrombin, is a potent enzyme and would be very destructive if 
free in the circulation. Therefore, the fast acting inhibitor, α2-antiplasmin, binds 
to any free Plasmin localising its action to the site of the thrombus. It can also 
bind to Factors V and VIII and fibronectin. The α2-antiplasmin can become 
crosslinked with Fibrin during polymerization, which makes Fibrin resistant to 
digestion by Plasmin. 
 
1.1.2.6. Fibrin degradation products and D-dimer 
 
When Plasmin binds to fibrin and cleaves the polypeptides the result are 
fragments known as fibrin degradation products (FDP). 
 
There are several types of FDP called X, Y, D, E and D-D or D-dimer. Similar 
non-crosslinked breakdown products are also formed. Some of these 
fragments inhibit haemostasis by either inactivating platelets or preventing 
fibrinogen to polymerize into fibrin strands. 
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1.2. Platelet overview 
 
Platelets are disc-shaped, non nucleated cells that are present in blood. They 
are involved in the cellular mechanisms of primary haemostasis leading to the 
formation of blood clots.  
 
They are formed and extruded from a megakaryocyte (MK) cytoplasm in the 
bone marrow and released in to the circulation where their life-span is 
approximately 9 to 10 days. With a diameter of 1.5 to 3μm they are the 
smallest cells that circulate in peripheral blood. In health the reference range 
is 150 to 400 x 109/l.  
 
The maturation process takes 4 to 5 days, where 2000 to 4000 platelets are 
released from every single Megakaryocyte (MK). Each day an adult produces 
100 x 109 platelets which can increase 10 fold in times of higher demand. 
 
The megakaryocyte-stimulating hormone, thrombopoietin (TPO), contributes 
to platelet count regulation via a primitive feedback loop. The majority of blood 
circulating platelets (20- 30%) are exchangeably sequestered within the 




1.2.1. Platelet structure and production 
 
1.2.1.1. Internal structure 
 
Platelets contain RNA, mitochondria, a canalicular system, a dense tubular 
system, cytoskeleton, several different types of granules, lysosomes, dense 
bodies and alpha granules (Fig. 1.5). The contents of the granules are 
























 Figure 1.5. Platelet internal structure (Hoffbrand et al. 2001) 
 
1.2.1.2. Granule contents 
 





1.2.1.2.1. Alpha Granules 
  
Alpha granules contain some coagulation factors, such as factor V, factor VIII 
and fibrinogen. The huge multimeric protein of von Willebrand Factor 
(involved in platelet adhesion and also a carrier for factor VIII in plasma), 
plasminogen activator inhibitor or PAI-1 (fibrinolytic inhibitor), α-antiplasmin, 
platelet derived growth factor and platelet factor 4 (neutralizes heparin effect) 
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1.2.1.2.2. Dense Granules 
 
Dense granules contain some agonists for platelet activation, for example 
adenosine triphosphate (ATP), adenosine diphosphate (ADP), serotonin (5-
hydroxytryptamine or 5-HT) (involved in platelet aggregation), epinephrine 
(stimulates platelets to aggregate), and calcium (involved in platelet 




Lysosomes are not involved in the platelet activation process. Lysosomes are 
cellular organelles that are involved in autophagy. Their contents are only 
involved in platelet metabolism and digestion. Amongst other molecules in the 
lysosomes, there are many digestive enzymes, like β-galactosidase, acid 
phosphate, α-mannosidase, β-glucosidase, β-N-acetylglucosaminidase and α-
fucosidase .  
 
 
1.2.2. Platelet functions 
 
- Adhesion  
- Activation and aggregation 
- Procoagulant activity 
 
Shear Stress in Flowing Blood 
Inside the vessels, blood flow is governed by hydrodynamic shear stress 
forces (Morawietz et al., 2008). Blood velocity is maximal at the centre of the 
blood vessel and approaches zero at the vessel wall. The shear stress of a 
vessel also depends on the flow rate, the diameter of the vessel, and fluid 
viscosity. These are critical parameters in vascular cell adhesion. 
 
The biggest blood cell types (e.g. white and red blood cells) tend to flow at the 
centre of the vessel leaving the vessel wall for the smaller cells, mainly 
platelets. This allows platelets to always be near a potential injury site.   
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1.2.2.1. Adhesion 
 
The mechanism of haemostasis starts when vessel damage occurs. At the 
site of injury the endothelial wall is not longer intact and this will let the blood 
components to be in contact with subendothelial microfibrils which will start 
and trigger haemostasis. At this point, several molecules, such as von 
Willebrand factor and collagen are able to access their specific platelet 
receptors, glycoproteins GPIb-IX-V and GPIa / GPVI respectively (Fig. 1.6). 
von Willebrand factor and collagen binding to the platelet wall receptors leads 

















Figure 1.6.  Platelet Adhesion (Hoffbrand et al. 2001) 
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1.2.2.2. Activation & aggregation  
 
In normal circumstances, platelets remain in their original, inactivated state. 
This is in part achieved by the action of the endothelium. In an intact blood 
vessel, the endothelial cells release prostacyclin or prostaglandin I2 (PGI2) 
which inhibit platelet activation (Fig. 1.7). 
 
When PGI2 is released into the circulation it binds to platelet membrane 
receptors and this generates an internal signalling that increases the amount 
of cytosolic cyclic adenosine monophosphate (cAMP).  
 
The direct consequence of increasing cAMP is that Calcium ions (Ca
2+) 
cannot be released from the dense tubular system (DTS), where they are 
stored. Ca2+ is needed for the platelet to go into a shape change. The actin 
and myosin fibers in the platelet cytoskeleton depend on Ca2+ to move.  























Figure 1.7. Inactivated platelet. (Hoffbrand et al. 2001) 
Abbreviations: Calcium ions (Ca2+), dense tubular system (DTS), 
cyclic adenosine monophosphate (cAMP).   
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When vessel damage occurs, platelets encounter a break in the endothelium 
where different molecules trigger their activation. The most common 
subendothelial molecule that activates platelets is collagen. There are few 
types of collagen that can do this, such as types I, III, and IV. (Saelman et al. 
1994). Collagen can be found in any part of the human body but not inside a 
blood vessel. There are many more molecules and enzymes that can activate 




The process of activation involves several platelet changes:  
 
Alpha and dense granules will release their contents by exocytosis. The 
release of Factor V, Factor VIII and fibrinogen triggers the coagulation 
pathway to generate more thrombin which will participate in the 
polymerisation of fibrinogen into fibrin. Secretion of these and other 
components will not only activate the platelet but will also attract more 
platelets to the site of injury and induce them to aggregate. 
 
The production of thromboxane A2 takes place in the platelet. Using the 
arachidonic acid pathway, the same pathway used by the endothelial cells to 
produce Prostacyclin. Thromboxane A2 reduces the amount of cytosolic  
cAMP. Lower cAMP induces the release of Ca2+ into the platelet cytoplasm 
from the dense tubular system.  
At this stage, the platelet is now ready to change its shape thanks to the extra 
Ca2+.  With the shape change, a new platelet receptor becomes active and 
available; this receptor is called GPIIb/IIIa and is necessary for platelets to 
aggregate, via fibrinogen binding.  This platelet receptor can also be used by 
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1.2.2.3. Procoagulant activity 
Platelets third function is to provide with a phospholipid membrane that works 
as a procoagulant surface where the tenase and prothrombinase complexes 
take place and a site for thrombin generation.  
To avoid excessive thrombin production on the surface of platelets, it is 
necessary activated protein C (APC) and protein S (cofactor) which will stop 
FVIII and FV to become active and therefore interfere with the coagulation 
cascade.  Lack of APC does not stop protein S from lowering thrombin 
generation (Sere et al., 2004).  
On the other hand, patients who have low protein C and S levels have a 
higher risk of thrombosis. Factor V Leiden, prothrombin G20210A mutations 
also give a much higher risk of developing a clot. (Young et al, 2003). 
 
1.3. Critically Ill patients 
 
1.3.1. Intensive Care Unit (ICU) 
 
An intensive care unit (ICU) is the area of a hospital that treats and monitors 
trauma or critically ill patients. 
Patients that end up in this department can come from the accident and 
emergency department, from a different ward or even straight from surgery. 
The ICU is a high technology, highly specialized and very expensive 
department.  
Not all ICUs are the same; some are more specialized than others, depending 
on the type of hospital they are in. Some just deal with severe injury or 
trauma. Many can be part of units treating for specific conditions such as 
heart, liver, kidney or neurological diseases. Others can specialise on a 
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Haematological  
Coagulation disorders and acquired coagulopathies are often seen in the ICU. 
The most common problems associated with haemostasis are liver disease, 
disseminated intravascular coagulation, anti-coagulant drugs, vitamin K 
deficiency and blood transfusions.  
First line of investigation in the ICU is to perform a clotting screen, which 
includes PT and APTT.  They also can measure the thrombin time, fibrinogen 
and D-dimer levels.  
 
1.3.2. APACHE scoring system 
 
The APACHE scoring system (Acute Physiology, Age, and Chronic Health 
Evaluation) is the gold standard tool in the ICU to accurately describe a 
patient‟s status and stability and to measure the risk of mortality once 
admitted in the hospital. 
 
APACHE has been updated 3 times. The original APACHE was developed in 
1981 at the George Washington University Medical Centre as a way to 
measure disease severity and it used 34 different parameters (Knaus et al., 
1981). APACHE II (Knaus et al., 1985) is a much more simplified version of 
the first APACHE; it only uses 14 physiological variables: 
 
1. Temperature - core 
2. Mean arterial pressure 
3. Heart rate 
4. Respiratory rate 
5. Oxygenation 
6. Fraction of inspired oxygen (FIO2)> 0.5 alveolar-
arterial oxygen tension difference (A-aDO2) 
7. FIO2 < 0.5 partial oxygen arterial pressure (PaO2) 
8. Arterial pH 
9. Serum sodium concentration 
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10.  Serum potassium concentration 
11.  Serum creatinine concentration 
12.  Haematocrit  
13.  White blood cell count  
14.  Glasgow coma score  
APACHE III (1991) uses data from 40 hospitals and more than 17,000 
patients (Wong et al., 1991). New variables were added to the APACHE III: 
15. Prior treatment location  
16. Disease requiring ICU admission 
 
APACHE III also takes into account patient's age and chronic as part of the 
scoring system. The final score will give a numerical value for predicted 
mortality. APACHE III is part of a very clever system which gets updates on 





Critically ill patients often develop some degree of acidosis. Acidosis is 
described as any pH lower than 7.35 or physiological pH. For humans pH is 
measured as arterial pH; one of the most common ways of testing it is by 
doing an arterial blood gas analysis. It is also necessary to look for the 
underlying condition that can be causing the low pH.  Acidosis is a serious 
complication of gravelly ill patients and therefore needs to be treated as an 
emergency. 
 
Physiological pH can fluctuate slightly between 7.35 and 7.45. Anything lower 
than pH 6.8 or higher than pH 7.8 in humans will be incompatible with life. 
Irreversible damage can be caused to the cells and tissues at these extreme 
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Acidosis is chemically speaking, a higher concentration of H+ in blood than in 
normal conditions.  Diseases like diabetes or simply starvation or even a bad 





Hypothermia in humans is defined as any body temperature lower than 37°C. 
Hypothermia is often seen in patients admitted in the ICU. Hypothermia is 
classified in three different stages (McCullough et al., 2004). 
 
Stage 1: Comprises body temperature between 36°C to 35°C, patient starts 
shaking and loses hand ability to perform precision tasks, numbness also 
appears.  Breathing is fast and shallow. Blood supply to arms and legs is 
lowered to avoid body temperature to fall even more, this is achieved by 
vasoconstriction.    
 
Stage 2:  at this stage body temperature has gone down to 35°C to 33°C, now 
the shaking has turned into strong shivering. Now the patient has lost most of 
his coordination, moving slowly and with difficulty. Vasoconstriction is higher 
now and the blood supply to arms and legs is almost zero because the body 
is trying to keep the warm blood to the vital organs.  Now the patient‟s skin is 
completely pale with even blue lips and ears.  
 
Stage 3: Anything below 32°C is considered as very dangerous temperature 
and hypothermia reaches its maximum level of severity. The patient now has 
lost his ability to walk or even to think properly or to be aware of what is 
happening. Blue pale skin is observed all around the body. Breathing rate 
slows down and heart starts racing. At this stage important organs start to 
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1.5.1. Temperature  
 
There are two main types of body temperature that can be measured. First, is 
the external or the also called peripheral temperature; this will drop first to 
avoid unnecessary lose of heat that is needed to keep vital organs warm. The 
second type is called core temperature; this is the important which needs to 








Screening tests provide an assessment of the „extrinsic‟ and „intrinsic‟ 
systems of blood coagulation and also the central conversion of fibrinogen to 
fibrin. 
 
1.6.2. Prothrombin Time 
 
With this assay the extrinsic coagulation pathway is timed. The factors directly 
involved are Prothrombin, fibrinogen and factors V, VII and X. PT assay only 
uses to main reagents which will be added to plasma obtained from citrated 
blood. These two main reagents are Thromboplastin and calcium. Normal 
reference PT times are between 10 and 14 seconds. (Hoffbrand et al., 2001). 
Any time delay on the PT will lead to further investigations on the factor levels 
involved. 
 
1.6.3. Activated Partial Thromboplastin Time 
 
This assay measures the also called intrinsic pathway. Many more 
coagulation factors are involved in the APTT, such as Prothrombin, fibrinogen 
and Factors VIII, IX, X, XI and XII. To perform an APTT three main reagents 
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are needed: firstly, something to trigger contact activation such as kaolin or 
silica; secondly, basic blood components need to be added to the plasma, 
these are calcium and phospholipids. Normal reference APTT times are 





1.6.4. Stago Start4® Analyser 
 
The STart® 4 is a coagulation analyzer that can be used to measure 
Prothrombin time, Activated partial thromboplastin time and thrombin time. It 
has a clot based detection system but with some modifications applied by 
Diagnostica Stago Company. This method is called Viscosity-based Detection 
System®. This technology allows the operator to run any plasma sample 
without having to discard the ones that have some degree of turbidity, such as 
samples with excess fat or lipaemic, etc. This is a big advantage compared to 
other optical clot detection methods. The STart® 4 analyser can run up to 4  
samples simultaneously at 4 independent cuvette locations.  
The system uses a steel ball inside a cuvette, the ball moves thanks to an 
electromagnetic field generated by to coils working in turns. When reagents 
are added to the plasma, time starts counting and the ball moves from side to 
side until clot formation. This will make the plasma so viscous that the ball 
cannot longer move. This will stop the clock. The machine finally, shows the 
clotting time on the screen (Fig. 1.8).  
 
 




The temperature of the cuvette can be adjusted down to 31°C.  APTT and 
PT were performed on this machine at different temperatures and different 
pHs. 
 
1.7. GLOBAL ASSAYS 
 
1.7.1. Calibrated Automated Thrombography (CAT) 
 
1.7.1.1. Principle of the Technique 
 
Calibrated Automated Thrombography (CAT) is a method that allows 
measuring Thrombin generation. The assay can be run on Platelet Poor 
Plasma (PPP) or Platelet Rich Plasma (PRP). 
The CAT uses a thrombin specific substrate that is added in excess. It is a 
fluorogenic substrate and once bound to thrombin emits fluorescence at 
specific wave length that is detected and registered by computer software.   
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Samples are run in two parallel assays at the same time. The first assay runs 
the sample with the reagents to trigger the coagulation system; the second 
assay runs the sample plus a calibrator, this will allow the machine to 
accurately calibrate the specific optical properties of any given plasma (i.e. 
optical density).  
Each patient‟s plasma absorbs light differently depending on the amount and 
types of molecules present in it. This is called “inner filter effect” (Hemker et 
al., 2002). 
 
The CAT software converts substrate + thrombin fluorescence to amount of 
thrombin. Once the assay is finished, the computer shows a graph with two 
axes. Amount of fluorescence will be expressed on the Y-axis and time on the 
X-axis; this is the raw curve obtained from a direct measurement of 
fluorescence. The amount of thrombin is proportional to the amount of 
fluorescence.  
 
The software makes a first derivative from the raw curve and the result is a 
bell shaped curve known as a “Thrombogram” (Fig. 1.9). On the 
Thrombogram the amount of thrombin (Y axis) is plotted against the time (X- 
axis) (Hemker et al., 2002).  
The thrombogram has several parameters: Lag time, peak, endogenous 
thrombin potential (ETP), time-to-peak and tail.   
 
 
1.7.1.2. Lag Time 
 
Lag time is the time it takes for the process of coagulation to begin, i.e. the 
first burst of thrombin production (Normally, around 10nmol of thrombin are 
formed). It is the first flat part of the thrombogram graph. It starts when the last 
reagent is added to the measurement well; in this case, CaCl2 and the 
thrombin substrate. The lag time is the equivalent of a clotting screen (APTT 
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1.7.1.3. Peak 
 
It is the maximum concentration of thrombin formed per unit time. 
 
1.7.1.4. Time to Peak 
 
It is the time that the sample takes to reach the peak of the thrombogram. 
 
 
1.7.1.5. Endogenous Thrombin Potential 
 
The Endogenous Thrombin Potential or ETP is the total amount of thrombin 
that a given sample can generate. It is represented in the Thrombogram as 






The tail of the thrombogram is the time at which the thrombin concentration 
comes back to zero.  
Alpha 2-macroglobulin is one the main inhibitors of thrombin. The substrate 
used in the CAT also binds to Alpha 2-macroglobulin + thrombin.  The CAT 
software automatically subtracts that fluorescence from the total and this is 



























Thromboelastography (TEG) was developed and described by Dr. Hellmut 
Hartert back in 1948. This assay looks at clot formation, time to clot, clot 
stability, clot strength and also the fibrinolytic pathway.  
The TEG is considered part of the global assays family, where the whole 





















Figure 1.9. Calibrated Automated Thrombogram 
Picture based on: http://www.haematologica.it/cgi/content/full/92/12/1639/F1921639 
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advantages of Thromboelastography is that it can be run even on whole 
blood. This means that all the blood components and red cells that are 
removed normally with spinning are still going to take part in the 
measurement. (Luddington et al., 2005). 
 
The ROTEM® or rotational thromboelastometry is frequently used during 
several types of surgery (such as cardiac surgery and liver transplantation) to 
monitor patient haemostatic status. The ROTEM® assay can give information 
to surgeons and doctors in no more than 30 minutes. Also the analyser is so 
compact and so simple to run that it can even be taken into the operation 
room. The ROTEM® has also been used in the ICU and where is has 
demonstrated it is a very good predictor any transfusion requirements 
(Kaufmann et al., 1997).  
 
 
Thromboelastometry has also many applications and advantages in the 
laboratory. Because it is a global assay is very useful In areas such as 
thrombophilia screening and prediction of thrombosis (Traverso et al., 1993; 
O‟Donnell et al., 2004). 
The haemophilia clinic also benefits from the use of the ROTEM®. Is very 
good monitoring treatments where recombinant factors are needed (Hayashi 
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                   1 oscillating axis                                  7 cuvette with blood sample 
                   2 counterforce spring                          8 fibrin strands & platelet aggregates 
                   3 light beam from LED                        9 heated cuvette holder  
                   4 mirror                                               10 ball bearing 
                   5 detector (electr. camera)                 11 data processing unit 
                   6 sensor pin 
 





The sample is placed inside a single-use cuvette in a warm cuvette holder. 
The detection sensor will be submerged into the sample that is inside the 
cuvette. This sensor is also attached to a rotating axis that turns 4.75° to the 
left and 4.75°  to the right alternatively.  
The analyser measures elasticity with the help of a spring attached to the 
rotating axis. The axis has a little mirror that serves to be located by a 
computer detector. Once clot formation occurs, a change in the viscosity and 
elasticity affects the movement of the rotating axis. Finally, this is registered 
by the computer which converts the signal into a thromboelastogram.  
 
 














1.7.2.3.1. Clotting time 
 
Clotting time (CT) is the time taken from the start of measurement until 
initiation of clotting (Fig. 1.11). It is a very useful parameter that helps on 
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1.7.2.3.2. Clot firmness 
Clot firmness is defined as the amplitude (mm) of thromboelastogram curve at 
any given time. 
 
 
1.7.2.3.3. Clot formation time 
Clot Formation Time (CFT) is the time (sec) taken from initiation of clotting 




1.7.2.3.4. Maximum clot firmness 
Maximum Clot Firmness (MCF) is the maximum width or amplitude (mm) of 
the thromboelastogram curve (Fig. 1.11). 
 
 
1.7.2.3.5. Maximum lysis 
Maximum lysis (ML) is the reduction (%) of the clot firmness after MCF in 
relation to MCF.  Fibrinolysis is defined when ML is bigger than 15% within 
1hour (Fig. 1.11). 
 




EXTEM as its name suggests is an assay that looks at the extrinsic pathway 
of the coagulation cascade. To initiate this test human tissue factor (TF) is 
added (as part of the EXTEM reagent) to the plasma sample.  
Only coagulation factors that are involved in the extrinsic pathway are the 
ones responsible for the results of this test. Fibrinogen and platelet defects 
can also affect the EXTEM results. 
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1.7.2.4.2. INTEM  
 
INTEM measures the intrinsic pathway of the coagulation cascade. INTEM 
reagent has some molecules that will initiate the coagulation cascade by 
contact activation. All intrinsic coagulation factors can affect this assay, such 
as prothrombin, fibrinogen and factors VIII, IX, X, XI and XII.  
Heparin contamination prolongs clotting times and alters all results obtained 
by INTEM.  
 
1.7.2.4.3. NATEM 
This is the simplest test run on the ROTEM®. Only calcium is added to the 
sample to initiate the haemostatic system.  
 
1.8. CONTACT INHIBITOR 
 
Corn trypsin inhibitor (CTI) is a small protein that is localized in the kernels of 
most species of corn. CTI is not only an inhibitor of trypsin, but is also a 
specific inhibitor of human factor XIIa. CTI binds to factor XIIa. This will result 
in an extension of the APTT when testing plasma + CTI but the PT will remain 


































Figure 1.12. Effect of CTI on the APTT and PT of normal human plasma 
(http://www.haemtech.com/Inhibitors_Substrates/CTI.htm) 
Abbreviations: Corn Trypsin Inhibitor (CTI), Activated Partial Thromboplastin 
Time (APTT), Prothrombin Time (PT).   
 
 
The Figure illustrates how CTI affects the APTT and PT of normal plasma 
(Figure 1.12.).   
 
The use of Corn Trypsin Inhibitor for the measurement of thrombin 
generation by calibrated automated thrombography (CAT). 
Contact factor-activated thrombin generation is completely inhibited at a CTI 
concentration of 18.3 μg/ml whole blood. Anticoagulation of blood is achieved 
by inhibition of the contact pathway by CTI (Luddington et al, 2004).  
Increasing the CTI concentration above this level did not lead to suppression 
of the TF-triggered ETP.  
 
 




-To study the effects of acidosis and/or hypothermia on the haemostatic 
process. 
-To establish reference physiological ranges of coagulation parameters under 
acidosis and hypothermia.  
-To develop a better protocol to monitor haemostasis on trauma and critically 
ill patients in the Intensive care unit. 
-To compare standard coagulation procedures with more advanced Assays, 
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2. Materials and methods 
2.1. Samples 
 
2.1.1. Method of bleeding 
Blood was collected from 40 consenting healthy adults and also from 17 
critically ill patients in the Intensive Care Unit at Addenbrooke’s Hospital, NHS 




Sample tubes used were S-monovette® 9NC (PFA) with a total capacity of 
3.8ml containing 0.129 mol/l of trisodium citrate and citric acid buffer solution 
pH 5.5 (0.38 ml citrate buffer solution) (Sarstedt Ltd, Leicester, UK). 
These tubes were chosen because they contained a buffer which would 
preserve the original pH of the sample. 
 
2.1.2.1. Corn Trypsin Inhibitor 
Corn Trypsin Inhibitor (12.66 µl CTI) (Haematology Technologies Inc., VT, 
USA) was added to each tube before use, giving a final concentration of 
1.45µmol/L of CTI. 
2.1.2.2. Buffers 
-Working buffer: (20mM Hepes, 140mM NaCl, 5 mg/ml BSA) 
-Fluo-Buffer: [875µl buffer (20mM HEPES, 60mg/ml BSA), 300µl 1M CaCl2 
and 75µl of fluorogenic substrate Z-Gly-Gly-Arg-AMC (diluted with 100mM 
DMSO)] 
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2.1.3. Processing & storage 
 
2.1.3.1. Platelet poor plasma 
To obtain platelet poor plasma (PPP) from whole blood, samples were 
centrifuged at 4000rpm (3578g) for 15 minutes. The plasma was separated 
into a 2ml Eppendorf tube using a Pasteur pipette. 
 
2.1.3.2. Platelet rich plasma 
To obtain platelet rich plasma (PRP) from whole blood, samples were 
centrifuged at 800 rpm (143g) for 8 minutes. The plasma was separated into a 
2ml Eppendorf tube using a Pasteur pipette. 
 
To be able to standardize the PRP, a final count of 150 x 109/L platelets was 
used for each PRP sample. To calculate this, the Beckman Coulter® LH750 
(Beckman Coulter, Miami, USA) was used to estimate the platelet number of 
a given sample, then the PRP was diluted proportionally with PPP from the 
same sample, to finally obtain the required 150 x 109/L platelet count. 
 
PPP samples were kept on ice for immediate use or frozen down at -80°C for 
later use. PRP samples were run within 6 hours and had to be kept at room 
temperature to avoid platelet activation/damage. 
 
When PRP was diluted with PPP, PPP had to be at room temperature before 
mixing to avoid a thermal shock which could affect the status of the platelets. 
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2.1.4. pH manipulation 
For the pH measurement of different samples a pH 210, Microprocessor pH 
Meter (Hanna Instruments, Ltd.) was used. This instrument has a sensor 
probe made of glass, which needs to be submerged into the sample tube to 
give a pH reading. 
 
pH was always measured at  room temperature. A duplicate sample was used 
to avoid possible contact activation with the glass probe of the pH meter. 
For correction or change of sample pH, sodium hydroxide (15.2M), AnalaR®, 
BDH, (VWR International Ltd.) or lactic acid (11.6M), AnalaR®, BDH, (VWR 
International Ltd.) were used. 
 
Both were diluted to 1:10 with deionized water because the reagents were too 
strong for the volume of plasma obtained from patient samples. 
 
Reagents were also pH manipulated with NaOH and/or lactic acid, to match 
the target pH of the experiment. 
 
Two different pH values were used for this study: a physiologic pH at 7.35 and 
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2.2. Automated assays 
 
2.2.1. The Calibrated Automated Thrombogram (CAT) 
A Fluoroskan Ascent® FL (Thermo Fisher Scientific Inc.) was used to run the 
CAT and the software used for this assay was ThrombinoscopeTM Software 
version 3.0.0.25. (Thrombinoscope BV, Maastricht, The Netherlands). 
 
2.2.1.1. Principle 
The phospholipid vesicles were prepared as described by Falls et al. (2000). 
The lipids were combined in the required proportions and dried under nitrogen 
at 45°C for 30 minutes and then resuspended in HEPES buffer (50mM 
HEPES, 145 mM NaCl, pH 7.1). The mixture was then passed through an 
extrusion device 11 times using a 100nm diameter polycarbonate filter. A 
further 21 passes were then performed through a 50nm diameter 
polycarbonate filter and the resultant vesicles were stored at 4°C until use. 
 
Test principle: 
The assay was performed as described by Hemker et al., 2003. Generally 
speaking, the machine runs two parallel assays for each sample; the first 
assay uses 20µl of thrombin calibrator and 80µl of sample plasma. This is 
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The second assay uses 10µl of 4µM of phospholipids vesicles, 10µl of 1.5pM 
of recombinant human tissue factor and 80µl of sample plasma. 
When the microplate is inserted into the Fluoroskan,  20µl of calcium chloride 
and the fluorogenic substrate, which have been mixed previously [875µl buffer 
(20mM HEPES, 60mg/ml BSA), 300µl 1M CaCl2 and 75µl of fluorogenic 
substrate (diluted with 100mM DMSO)] were added by an automated 
dispenser to all the wells in use. With a final volume of 120µl the reaction 
initiated and was monitored by Thrombinoscope software. 
 
2.2.1.2. Reagents 
-Thrombin Calibrator, Thrombinoscope BV, Maastricht, The Netherlands. 
-Recombinant human tissue-factor, Dade® Innovin®, Dade Behring, Germany. 
-Phospholipid Vesicles (see 2.4.1 preparation of phospholipid vesicles) 
-Fluorogenic Substrate Z-Gly-Gly-Arg-AMC (Bachem, Dubendorf, 
Switzerland) 
-Calcium chloride (BDH Ltd, Poole,UK) 
-HEPES (BDH Ltd, Poole,UK) 
-Bovine Serum Albumin (BSA)(Sigma Aldrich Ltd, Poole UK) 
-Dimethyl sulphoxide (DMSO) (Sigma Aldrich Ltd, Poole UK) 
 
Preparation of Phospholipid vesicles: 
Instrumentation and consumables: 
Extrusion device (Avestin, Ottawa, Canada) 
Polycarbonate filters (Glen Creston, Middlesex, UK) 
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Reagents: 
Synthetic phospholipids in chloroform (Avanti Polar Lipids, Alabama, USA): 








Thrombin calibrator was used as described in Section 2.2.1.2. 
 
2.2.1.5. Plates 
The Fluoroskan Ascent® FL uses 96 well microplates, Blue, U-shape (Greiner 
Bio-One GmbH, Germany). This plates allows to run up to 24 samples at a 
time (each sample needs 2 wells with the calibrator + 2 wells with the sample). 
 
2.2.1.6. Temperature adjustment 
The temperature was set through the Thrombinoscope software. 
By the time the reaction starts the microplate and all of the assay components 
in the wells are already at the required temperature. The incubator 
temperature range is from room temperature +3°C to +45°C, when ambient 
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2.2.1.7. pH adjustment 
All reagents and plasma samples were adjusted with lactic acid (1.16M) 
and/or sodium hidroxide (1.52M) to obtain the pH value required, before 
commencing the reaction. 
 
2.2.1.8. The measurement 
Thrombinoscope software monitors the reaction by detecting the fluorescence 
emitted by the cleaved fluorogenic substrate. The filters on the Fluoroskan 
have an excitation wavelength from 320nm to 700nm and an emission 
wavelength range from 360nm to 670nm. The signal is monitored on intervals 
of 30 seconds during the whole length of the assay. 
Thrombinoscope TM converts the direct reading of emitted fluorescence into 
units of thrombin (mmol) to produce a raw curve. A first derivative is obtained 
from the raw curve, giving a classic bell shaped curve where parameters such 
as: Lag time, peak and time-to-peak can be derived (Hemker et al., 2003). 
Thrombinoscope TM also subtracts the α2-macroglobulin bound thrombin 
contamination from the bell shaped curve, bringing it back to baseline; 
therefore creating a curve tail and delimiting the area under the curve or 
endogenous thrombin potential (ETP). 
 
2.2.2. The TEG 
The system is called rotational thromboelastometry (ROTEM®) (Pentapharm 
Gmbh, Munich, Germany), with a four channel measurement unit and an 
electronic pipette in station. The software is already incorporated in the 
analyzer. 
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2.2.2.1. Principle 
The ROTEM can run five different types of assays. The one used for this 
study was the EXTEM Assay. This is a fast assessment of clot formation, 
fibrin polymerisation and fibrinolysis via Tissue factor activation. It uses 20µl 
of Star-TEM®20, 20µl of Ex-TEM® and 300µl of plasma (PPP/PRP). 
 
2.2.2.2. Reagents 
-Star-TEM®20 (0.2 mol/l of CaCl2 in HEPES buffer pH7.4 and 0.1% NaOH) 
(Pentapharm Gmbh, Munich, Germany). 
-Disposable cups and pins (Pentapharm Gmbh, Munich, Germany). 
 
2.2.2.3. Sample preparation 
Whole blood samples extracted using a citrated tube (S-Monovette 3.8ml 
9NC PFA). 
PRP and PPP samples were obtained from whole blood as described in 
Sections 2.1.3.1 and 2.1.3.2. 
 
2.2.2.4. Controls  
No control samples were required for this assay. 
 
2.2.2.5. Temperature adjustment 
The temperature was set before running the analysis, through the software 
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2.2.2.6. pH adjustment 
All reagents and plasmas were adjusted with lactic acid (1.16M) and/or 1:10 
sodium hidroxide (1.52M) to obtained the pH value required, before 
commencing the reaction. 
 
2.2.2.7. The measurement 
Blood was added to a disposable cuvette in a heated cuvette holder. A 
disposable pin (sensor) was fixed on tip of the rotating axis and this axis is 
guided by a high precision ball bearing system.  
The axis rotates back and forth and is connected with a spring for 
measurement of elasticity. The exact position of the axis is detected by 
reflection of light on small mirror on axis. The loss of the elasticity when the 
sample clots, leads to a change in the rotation of the axis.   
Once the data is obtained, are then analysed on a computer and visualised in 
a thromboelastogram.  
 
2.2.3. The START4 
Manual APTT and PT (STart® 4). The STart® 4 (Stago Diagnostica Ltd., 
USA) semi-automated haemostasis analyzer features the method of Electro-
mechanical Clot Detection® (Viscosity-based Detection System). The system 
uses a steel ball inside a cuvette, the ball moves thanks to an electromagnetic 
field generated by to coils working in turns. When reagents are added to the 
plasma, time starts counting and the ball moves from side to side until clot 
formation. This will make the plasma so viscous that the ball cannot longer 
move. This will stop the clock. The machine finally, shows the clotting time on 
the screen.  
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2.2.3.1. Prothrombin time 
 
PT reagents: 
Human Thromboplastin, Simplastin® HTF (BioMerieux Inc., USA) 
 
PT Assay: plasma 100µl was added to a cuvette and incubated at the set 
temperature for 1 minute. After this, 200µl of Simplastin® HTF was added and 
the reaction initiated. 
 
2.2.3.2. Activated partial Thromboplastin time 
 
APTT reagents: 
- Micronized-Silica [0.175g of Fumed Silica 99.8%; Sigma-Aldrich Chemie      
Gmbh., Germany in 100ml of MDA® Imidazole buffer (Diluent) (Trinity 
Biotech, USA)]. 
- Platelet substitute, Diagen® (Diagnostic Reagents Ltd., Oxon, UK) 
- 0.025M Calcium Chloride  (BioMerieux Inc., Durham, UK). 
 
APTT Assay: platelet substitute (50µl), 50µl of micronised–silica and 50µl of 
plasma were incubated for 4 minutes. To initiate the coagulation cascade, 
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2.2.3.3. Sample preparation (PPP, PRP) 
PPP and PRP were obtained as described before in Sections 2.1.3.1. and 
2.1.3.2. 
 
2.2.3.4. Temperature adjustment 
The assay temperature of the Start®4 was set in the range 31°C to 40°C. The 
current temperature of the analyzer was constantly shown on the liquid crystal 
screen. 
 
2.2.3.5. pH adjustment 
All reagents and plasma samples were adjusted with lactic acid (1.16M) 
and/or sodium hydroxide (1.52M) to obtain the pH value required, before 
commencing the reaction. 
 
2.2.3.6. The measurement 
PT or APTT Assays were selected from the menu. The attached automated 
pipette has become active and ready to load the reagents and the plasma into 
the cuvette containing a ball bearing in it. The reaction began and the timer 
started counting until the clot was so solid that the ball bearing could not move. 
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2.3. Statistical software 
SPSS Statistics (PASW Statistics 18) software was used 
(www.spss.com/statistics/).  
Data obtained from this study needs to be distributed in several groups 
according to the different parameters used (mainly temperature and pH) and 
the different assays used (PT, APTT, CAT and ROTEM). When comparing 
two or more groups of data, is not possible to use a t-test comparison 
because of the problem of multiple testing. The best option is to use a one-
way analysis of variance (ANOVA). With ANOVA it is possible to find out if the 
means of the populations differ. 
When ANOVA leads to a conclusion that there is evidence that the group 
means differ, it is necessary to investigate which of the means are different. 
This is where the Tukey multiple comparison test is used. The test compares 
the difference between each pair of means with appropriate adjustment for the 
multiple testing. The results are presented as a matrix showing the result for 
each pair, as a P-value, p values of <0.05 were considered significant. The 
Tukey multiple comparison test, like ANOVA, assumes that the data from the 
different groups come from populations where the observations have a normal 
distribution and the standard deviation is the same for each group.  
T-test for Equality of Means was also used for simpler comparisons 
between two different groups of data. 
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3. PROBLEM SOLVING 
 
 
3.1. pH measurement & sample activation. 
 
It quickly became apparent that, somehow, the pH manipulated samples were 
activated. Consequently, the whole pH manipulation process was analyzed 
and investigated. 
 
A pH 210, Microprocessor pH Meter (Hanna Instruments, Ltd.) was used to 
measure sample pH. This pH meter has a probe which needs to be 
submerged into the sample. The probe is made of glass and this could be a 
problem. Glass is negatively charged and behaves as a potent solid phase 
activator of the contact activation process (Sánchez et al, 2002).  When 
plasma comes in contact with glass, FXII becomes activated as the βFXIIa 
form and therefore the coagulation cascade is initiated. 
 
Importantly, the samples used for this study had CTI which limits endogenous 
sample contact activation (Luddington et al, 2004). CTI is not only specific for 
trypsin but it is also capable of inhibiting FXIIa from the plasma. With no FXIIa 
coagulation can not be initiated. 
 
The concentration of CTI used is sufficient to prevent the endogenous contact 
activation associated with sample collection and separation. However, it is not 
sufficient to prevent the additional challenge of contact with a glass surface as 
presented in the pH probe. This effect can be demonstrated by using the 
ROTEM®. When a CTI treated whole blood sample is run on the analyzer, the 
graph obtained should be a completely flat line following adding the calcium. 
However, eventually the CTI becomes overwhelmed by the contact activation 
surface of the ROTEM® cuvette and following a prolonged lagtime a normal 
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3.2. pH measurement design. 
 
To investigate the possibility that the pH meter probe activated the sample, 
ten samples were run in duplicate. Half of the duplicate samples had glass 
probe contact for a minute while the other half did not have any contact. All 
the duplicates were run with the CAT under the same conditions. Results are 













No probe contact 5.14 281.3 8.26 1750 
SD 0.41 15.54 0.53 40.44 
Probe contact 5.09 266.8 8.01 1730 
SD 0.18 11.8 0.19 33.72 
  
Table 3.1. pH Meter probe activation measurement 
Abbreviations: time to peak (ttPeak), endogenous thrombin potential (ETP). 
 
 
Although these results were not very conclusive they demonstrated that the 
glass probe contact alone seemed not to produce any significant changes. 
This test was not the same as performing pH manipulation. There were also 
reagents used to change the pH which could trigger sample activation. 
 
 
3.3. pH regulation and sample activation. 
 
To be able to modify the plasma pH, a physiologic acid (lactic acid) and a 
base (NaOH) were required; this could affect the stability of plasma 
components and induce plasma activation. 
Both, acid and base were diluted down to 1:10 from the bottle source, this 
way the pH shock would be reduced. The final concentration used was 
sodium hydroxide 1.52M and lactic acid 1.16M. Special care had to be taken 
with PRP plasma samples, due to the fact that platelets are very fragile and 
very prone to become activated. 
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3.4. pH regulation strategy. 
 
 
A study was designed to examine if the sample pH manipulation induced 
sample activation. Two different approaches were used (Table 3.2.): 
- 1st method: the sample pH is changed down to target pH value, measured 
with the pH meter and then run in the CAT. 
- 2nd method: the sample pH is changed and measured in a duplicate sample 
until the target pH is obtained, then the amount of acid or base used, is 
recorded and added to the an identical sample but, this time, no sample 
measurement is taken. 
 
The results were as follows: 
 
 












4.48 398.5 6.59 2347.9 
0.33 13.8 0.56 257.4 
2nd method 
standard deviation 
5.17 270.5 8.46 1733.3 
0.13 22.7 0.21 62.9 
 
Table 3.2. Possible sample activation by pH manipulation. 10 samples were 
used for each method (n=10).  
Abbreviations: time to peak (ttPeak), endogenous thrombin potential (ETP). 
 
 
Comparing results from the 1st and 2nd methods, lag times and time to peak 
were shorter, peaks were higher and ETPs were increased. Clearly the 
samples used with the first method were activated by the pH manipulation 
process. This suggested that the 2nd method was much more appropriate for 
this study, where samples remained at their baseline values and this 
approach was used throughout the study. 
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3.5. Fresh samples compared to frozen & thawed samples. 
 
It is well documented in the literature that the process of sample storage, 
involving freezing and thawing samples, generates sample activation by cold 
induced contact activation (Norda et al., 2008). This was demonstrated by 
Palmer et al. (1982) who reported shorter times to clot in the PT and APTT in 
frozen and thawed samples compared to fresh. 
  
Thromboelastometry was used to compare fresh against frozen & thawed 
samples. Five samples were separated in different aliquots. The fresh ones 
were run immediately after separation and the rest were frozen (-80°C 
freezer) and thawed a week later for measurement. 
 
Because PPP was used the EXTEM was the assay of choice. The results 
between the five fresh samples and the five frozen & thawed F&T) are shown 

















Fresh 79 2595 67.2 19.4 1972.6 11 101 
SD 7.55 552 2.59 1.14 86.6 0.71 2.91 
Frozen & 
Thawed 
44.2 9526.2 69.2 13.4 1410 11.2 53.2 
SD 4.49 933.7 1.1 0.89 129.3 0.45 4.71 
 
 
Table 3.3. Results from fresh samples and frozen & thawed samples 
Abbreviations: clotting time (CT), clot formation time (CFT), Alpha (α), 
maximum clot firmness (MCF), area under the curve (AUC), maximum 





47 CHAPTER III: PROBLEM SOLVING 
 
These results clearly show the effects of freezing and thawing on clotting 
profiles. 
The clotting time (CT) was almost shortened by a half when using frozen & 
thawed plasma (from 79sec down to 44.2 sec). Clot formation time (CFT) 
experienced the opposite effect where times were much more prolonged with 
the freezed and thawed PPP. MCF, AUC and MAXV-t were higher on the 
fresh samples. Alpha (α) and MAXV however remained stable. 
 
Overall, these results agree with previously published information about the 
so called cold-activation phenomenon. Fresh and thawed samples become 
activated by a temperature effect and also coagulation factor levels (such as 
FVIII and von Willebrand Factor) can drop down to 50% of the original levels 
(Favaloro et al, 2004). This explains the different changes seen with the 
ROTEM.   
The cold activation phenomenon is responsible for the reduction of the CT. 
Consequently, the coagulation factors depletion produces a prolonged and 
lower MCF, AUC and MAXV-t following freezing and thawing of the samples. 
 
To avoid the freezing and thawing effects, this study was performed on fresh 
samples. The only way to achieve this was by bleeding the healthy volunteers 
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4. RESULTS 
 
4.1. Introduction:  
The effects of Hypothermia and Acidosis on Haemostasis. 
 
It is well documented that in severe to moderate hypothermia the coagulation 
screens, such as prothrombin time (PT) and activated partial thromboplastin 
time (APTT), experience a time prolongation in patients with normal factor 
levels. (Reed, 1990). This haemostatic delay has been proposed as an 
increased haemorragic risk (Gubler et al, 1994; Breen et al., 1988; Armand et 
al., 2003). 
In addition, some studies suggested that trauma patients with hypothermia 
suffer from coagulopathy which increases the mortality rate in the ICU (Patt et 
al, 1988). 
In vitro studies investigated the effects of hypothermia (temperatures down to 
25°C), showed time prolongation on APTT, PT and thrombin times (TT) (Reed 
et al, 1992). Another study of 45 patients, who were hypothermic and acidotic, 
revealed that they developed clinically significant bleeding despite adequate 




4.2.1. Clotting tests: PT/APTT 
 
To reproduce these findings, the Start4 analyzer was used to perform PT and 
APTT assays under hypothermic and acidotic conditions respectively and in 
combination, on 10 different samples from healthy volunteers (Table 4.1.).  
 
Four different experiment conditions were tested: 
 
a) Physiological conditions (Temperature 37°C and pH 7.35) 
b) Hypothermia (Temperature 31°C and pH 7.35) 
c) Acidosis (Temperature 37°C and pH 6.9) 
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T37°C / pH 7.35 12.24 0.4 110.53 5.44 
T31°C / pH 7.35 17.91 1.84 114.41 11.45 
T37°C / pH 6.9 15.17 0.32 147.18 7.17 
T31°C / pH 6.9 21.54 1.79 169.27 15.06 
 
Table 4.1. Mean values and standard deviation (SD) on 10 patients for PT 
and APTT using platelet poor plasma under normal, hypothermic and/or 
acidotic conditions. 
Abbreviations: platelet poor plasma (PPP), prothrombin time (PT), activated 
partial thromboplastin time (APTT). 
 
 
Prothrombin times using platelet rich plasma (PRP) were performed without 
any added phospholipids. This could not be done on the analyzer due to the 
fact that the PT reagent used for the test (Simplastin HTF) used a lipidated 
tissue factor. For that reason only APTT was measured on PRP (Table 4.2.).  
 
 




T37°C / pH 7.35 118.2 15.39 
T31°C / pH 7.35 136.6 18.11 
T37°C / pH 6.9 147.5 20.99 
T31°C / pH 6.9 162.4 12.59 
 
Table 4.2. Mean values and standard deviation (SD) on 10 patients for APTT 
using platelet rich plasma under normal, hypothermic and/or acidotic 
conditions. 
Abbreviations: platelet rich plasma (PRP), prothrombin time (PT), activated 
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4.2.1.1. Discussion 
 
These results confirm those reported by Reed (1990). Hypothermia prolonged 
the PT by more than 5 seconds and the APTT for almost 4 seconds on the 
PPP samples. PRP APTT was also prolonged under hypothermic conditions 
by more than an 18 seconds delay. 
 
Acidotic conditions prolonged the PT for almost 3 seconds and the APTT by 
more than 36 seconds on the PPP samples. PRP APTT was also delayed by 
29 seconds. 
 
The combined effect of hypothermia and acidosis increased further the delays 
observed above. The PT was prolonged by more than 9 seconds and the 
APTT by 58 seconds on the PPP samples. The PRP APTT showed a delay of 
44 seconds at 31°C of temperature and pH 6.9 compared to normal 
conditions. 
 
These results showed that either hypothermia or acidosis have an effect on 
the coagulation process in vitro, by delaying PT and APTT clotting times. PT 
at 31°C/pH7.35 and PT at 37°C/pH6.9 were significant (p<0.01) (Table 4.1.). 
The combined effect of hypothermia and acidosis made the PT/APTT time 
delays even longer, suggesting a possible cumulative effect of the two 
parameters over the coagulation process. PT at 31°C/6.9 was very significant 
(p<0.01) (Table 4.1.). 
 
The progressively prolonged PT and APTT times observed in vitro under 
hypothermic and/or acidotic conditions suggest that unless temperature 











51 CHAPTER IV: RESULTS 
4.2.2. Calibrated Automated Thrombogram results 
 
With the clot based assays like PT or APTT, the only parameter that could be 
measured was the time taken to clot formation.  
 
The CAT not only measured a specific parameter but several in a continuous 
measurement which ends when there is no more Thrombin to be generated 
by a sample. This is achieved by a fluorescence technique that allows the 
measurement to be carried out after the clot has formed. Generally speaking, 
it gives an overview of the general haemostatic potential of the patient 
sample.  
 
Several parameters can be measured from this assay: 
 
(i) Lag Time: This is the time needed for clot formation. This normally 
happens when approximately 20nmol of Thrombin are formed. 
 
(ii) Peak: It measures the maximum rate of Thrombin formation per unit 
time. 
 
(iii) Time to Peak: It is the time taken to Peak from the reaction start to 
the Peak formation. 
 
(iv) Endogenous Thrombin Potential (ETP): This measures the total 
amount of Thrombin that a given sample can generate. It correlates 
with the area under the curve. 
 
(v) Start Tail: starts when there is no more Thrombin left on the 
sample and the CAT curve reaches the baseline. 
 
(vi) Velocity: This parameter measures the thrombotic capacity of the 
sample. This value is obtained by calculating the slope of the CAT 
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To compare results with the clotting methods, the same conditions were used 
for assays under hypothermic and acidotic conditions using samples from 10 
healthy volunteers: 
  
a) Physiological conditions (Temperature 37°C and pH 7.35) 
b) Hypothermia (Temperature 31°C and pH 7.35) 
c) Acidosis (Temperature 37°C and pH 6.9) 
d) Hypothermia and Acidosis (Temperature 31°C and pH 6.9) 
 
The CAT Results were as follows: 
 
 
4.2.2.1. Calibrated Automated Thrombogram. Platelet poor plasma 
 
A Lag Time delay was seen with hypothermic and acidotic conditions, 
respectively, but not statistically significant p>0.05. When hypothermia and 
acidosis were combined the delay was greater (2.55 minutes delay) (Table 
4.3) with p<0.01 (Table 4.4.). 
 
The overall ETP increased with acidosis and experienced a greater increment 
with hypothermia and with hypothermia + acidosis (Table 4.3) with p<0.01 
(Table 4.4.). 
 
Peak changes were not significant. The peak increased with hypothermia 
alone and showed little change with acidosis or when the two were combined.  
 
The time-to-peak followed the same trend as the lag time for all the different 
combinations tested. 
 
In hypothermia alone, the velocity slightly decreased but in acidotic conditions 
it decreased down to 28.7°C. The lowest value for velocity was seen at 31°C 























SD Velocity SD 
37°C /pH 7.35 7.91 1.4 1777 458 191 66.8 13.3 1.79 36.7 15.7 
31°C /pH 7.35 8.37 1.4 2681 475 227 60.2 15.1 2.22 35.4 12.9 
37°C /pH 6.9 8.22 1.4 1985 432 180 53.2 14.7 1.79 28.7 11.6 
31°C /pH 6.9 10.46 1.5 2852 489 202 61.7 19.2 2.21 25.2 13.2 
 
Table 4.3. CAT Results on PPP for normal, hypothermic, acidotic and 
hypothermic+acidotic conditions. 
Abbreviations: platelet poor plasma (PPP), endogenous thrombin potential 
(ETP), time to peak (TT Peak). 































Fig.4.1. PPP Thrombin generation curves for normal, hypothermic, acidotic 
and hypothermic+acidotic conditions.  
Abbreviations: platelet poor plasma (PPP). 
T         pH 
Platelet Poor Plasma 
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The figure (Fig.4.1.) shows four different CAT curves for the thrombin 
generation assay. Due to the increment in lag time, a shift of the curves to the 
right was observed when using the abnormal conditions. 
In spite of the peak heights, the “area under the curve” or ETP were increased 
for the three abnormal conditions when comparing it with (blue curve) 
physiological conditions (T=37°C/pH7.35). 
 





















31/6.9 -2.55 P<0.01 -4.19 -.91 
31/7.35 -.47 NS -2.11 1.17 




31/6.9 -1075.52 P<0.01 -1526.5 -624.48 
31/7.35 -904.49 P<0.01 -1355.5 -453.45 




31/6.9 -11.04 NS -74.80 52.73 
31/7.35 -35.96 NS -99.73 27.80 




31/6.9 -5.91 P<0.01 -8.35 -3.47 
31/7.35 -1.77 NS -4.20 .66 
37/6.9 -1.37 NS -3.81 1.06 
Velocity 37/7.35 
31/6.9 12.07 NS -2.59 26.73 
31/7.35 1.31 NS -13.35 15.97 




31/6.9 -9.30 P<0.01 -10.87 -7.72 
31/7.35 -5.67 P<0.01 -7.24 -4.09 




31/6.9 -41.95 NS .000 -56.26 
31/7.35 12.91 NS .090 -1.40 
37/6.9 -19.87 NS .003 -34.18 
 
Table 4.4. Statistical data on PPP for temperature and pH combinations. This 
table shows the comparison of data obtained at 37°C/pH7.35 with data obtained 
at 31°C/pH6.9, 31°C/pH7.35 and 37°C/pH6.9 respectively. This contains data 
from the different CAT parameters and also PT and APTT times. P values of 
<0.05 were considered significant (in blue). Non significant p values are 
expressed as NS (in red). Abbreviations: endogenous thrombin potential (ETP), 
time to peak (TT Peak), prothrombin time (PT), Activated Partial Thromboplastin 
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4.2.2.2. Calibrated Automated Thrombogram. Platelet rich plasma results 
 
For the lag time, the same trend was seen as with the PPP (Table 4.5.). Time 
delays were observed using hypothermic and acidotic conditions but when 
both conditions were combined the delay was even greater (p<0.01) (Table 
4.6.). 
 
The Endogenous Thrombin Potential (ETP) followed the exact same trend as 
the PPP, It was increased with both conditions respectively and when run with 
both, the increment was more pronounced (Table 4.5.). Results were 
statistically significant for hypothermia (p<0.01) and for hypothermia + 
acidosis (p<0.01) (Table 4.6.). 
 
Overall, the peak heights increased under hypothermic and acidotic 
conditions, but these changes were not significant (Table 4.6.). 
 
The time-to-peak was increased with hypothermia but not with acidosis. 
 
Velocity for PRP did not follow any particular pattern and the results were not 


















SD Velocity SD 
37°C /pH 7.35 6.28 0.9 1760.55 356 112 46.6 16.1 2.3 11.35 15.4 
31°C /pH 7.35 7.52 1.5 2196.1 262 122 36.1 19.3 3.8 10.33 18.1 
37°C /pH 6.9 7.12 1.0 2036.75 352 163 42.2 15.4 1.8 19.61 6.2 




Table 4.5. CAT Results on PRP for normal, hypothermic, acidotic and 
hypothermic+acidotic conditions. Abbreviations: platelet rich plasma (PRP), 
endogenous thrombin potential (ETP), time to peak (TT Peak). 

































Fig.4.2. PRP Thrombin generation curves for normal, hypothermic, acidotic 
and hypothermic+acidotic conditions. Abbreviations: platelet rich plasma 
(PRP). 
 
The results obtained (Fig.4.2.) show that under hypothermic, acidotic and 
hypothermic + acidotic conditions the CAT curves were moved to the right due 
to a Lag Time delay. 
 
The results also clearly demonstrated that the “Area under the curve” or ETP 
is increased in the presence of hypothermic and acidotic conditions, either 
alone or in combination. 
 
The changes become more obvious when comparing the blue line 
(T=37°C/pH7.35) and the red line (T=31°C/pH6.9) which shows the changes 
on the CAT assay when comparing physiological conditions to the combined 
effect of hypothermia and acidosis. 
T       pH 
Platelet Rich Plasma 
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31/6.9 -2.55 P<0.01 -4.19 -.91 
31/7.35 -.47 NS -2.11 1.17 




31/6.9 -1075.52 P<0.01 -1526.5 -624.48 
31/7.35 -904.49 P<0.01 -1355.5 -453.45 




31/6.9 -11.04 NS -74.80 52.73 
31/7.35 -35.96 NS -99.73 27.80 




31/6.9 -5.91 P<0.01 -8.35 -3.47 
31/7.35 -1.77 NS -4.20 .66 
37/6.9 -1.37 NS -3.81 1.06 
Velocity 37/7.35 
31/6.9 12.07 NS -2.59 26.73 
31/7.35 1.31 NS -13.35 15.97 




31/6.9 -41.95 NS .000 -56.26 
31/7.35 12.91 NS .090 -1.40 
37/6.9 -19.87 NS .003 -34.18 
 
Table 4.6. Statistical data on PRP for temperature and pH combinations. This 
table shows the comparison of data obtained at 37°C/pH7.35 with data 
obtained at 31°C/pH6.9, 31°C/pH7.35 and 37°C/pH6.9 respectively. This 
contains data from the different CAT parameters and also APTT times.  
P values of <0.05 were considered significant (in blue). Non significant p 
values are expressed as NS (in red). Abbreviations: endogenous thrombin 
potential (ETP), time to peak (TT Peak), prothrombin time (PT), Activated 






The use of two different types of plasma samples, Platelet Poor Plasma (PPP) 
and Platelet Rich Plasma (PRP) demonstrated that some parameters stayed 
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The lag time and the ETP were coherent for both types of plasma but the 
peak, ttPeak and velocity did not show good correlation between PPP and 
PRP. 
 
With the CAT there seems to be a disparity between some of the results 
obtained from the different parameters. 
 
When tests were run under a critical condition, the lag times were delayed 
giving a general and classical coagulopathy profile where the time to clot 
formation became prolonged. 
 
Conversely, the overall ETP (which is the most important parameter in this 
assay) did not seem to follow the same bleeding pattern. Much more thrombin 
was generated under hypothermic or acidotic conditions alone and with the 
low temperatures and acidic conditions combined; the increment on the ETP 
became even more conspicuous. 
 
In general, it seems that both parameters (lag time and ETP) are affected by 
both hypothermic or acidotic conditions on there own but when combining 
both of them together (hypothermia + acidosis) there was a cumulative effect 
which exaggerated the changes even more. 
 
These particular observations have not been observed previously in any 
published literature to date, where a hypocoagulable coagulopathy is 
described under abnormal conditions, such as hypothermia and acidosis.  
 
These CAT results obtained using hypothermic or acidotic conditions suggest 
that in spite of having first a delayed lag time, once the thrombin burst occurs 
it will generate more thrombin which will increase the overall ETP. Therefore a 
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4.2.3. ROTEM® Results  
 
The Assay used the ROTEM® was the EXTEM® for an assessment of clot 
formation, fibrin polymerisation and fibrinolysis via Tissue factor activation. 
With the ROTEM® only Platelet Poor Plasma (PPP) was used for this study.  
 
 
4.2.3.1.ROTEM® results. EXTEM® using Platelet poor plasma  
 
The Clot Formation Times (CFT) demonstrated an average 209.7 seconds 
delay under hypothermic conditions and 212.8 seconds delay under acidotic 
conditions. When tested at 31°C/pH 6.9 the CFT was markedly delayed, rising 
to a mean value of 615.9 seconds, which meant a delay of 437.9 seconds, 
more than three fold increases compared to physiological conditions (Table 
4.7.). 
The Alpha (α) parameter only was affected on the two tests when acidotic 
conditions were tested. Hypothermia did not seem to have any effect. 
MCF under physiological conditions was 18.8 mm, when hypothermic and 
acidotic conditions were used separately. The results showed a slight 
decrease that did not achieve statistical significance. 
When hypothermic and acidotic conditions were combined a greater effect on 
the MCF (T 31°C/pH 6.9) was observed (15.6 mm) (Table 4.7.). 
 
EXTEM®  











37°C /pH 7.35 178.0 55.3 72 3.65 18.8 3.52 
31°C /pH 7.35 387.7 88.4 71.8 3.52 18.5 2.88 
37°C /pH 6.9 390.8 106.9 66.4 5.23 18.1 2.42 
31°C /pH 6.9 615.9 153.6 62.1 9.13 15.6 2.72 
 
Table 4.7. ROTEM® results. EXTEM® on PPP for normal, hypothermic, 
acidotic and hypothermic+acidotic conditions. Abbreviations: clot formation 
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4.2.3.1.1. Discussion 
 
All of these results indicate a clear tendency for a coagulopathy in critical 
conditions. The times to clot were significantly prolonged, the clot formation 
rates were decreased and clot stability worsened. To summarize, The 
EXTEM® assay results suggest than under the effects of hypothermia and 
acidosis there is not only a delay in clot formation but also a much weaker and 
unstable clot formed, which will be dissolved sooner by the fibrinolytic 
process.  
 
4.2.3.2. ROTEM® results. (Whole blood) 
The ROTEM® was the only technology used in this study that had the 
capability of performing an assay for whole blood. The assay is called 




















37°C /pH 7.35 487.3 155 61.1 54.8 5494.2 9.67 600.1 
SD 134 53.5 8.3 5.3 508 2.7 184 
31°C /pH 7.35 584 229.7 53 54.3 5469.6 6.78 686.7 
SD 202 73.9 10.5 6.2 628 2.8 235 
37°C /pH 6.9 549 148.2 62.4 57.4 5793.1 9.7 607.3 
SD 73 28.2 4.4 6.1 648 2.1 61 
31°C /pH 6.9 754.8 476.6 41 43.6 4460.4 4.7 937.5 
SD 243 31.2 15.6 8.7 934 2.4 484 
 
 
Table 4.8. ROTEM® Results on whole blood using the NATEM® Assay for 
normal, hypothermic, acidotic and hypothermic+acidotic conditions. 
Abbreviations: clotting time (CT), clot formation time (CFT), Alpha (α), 
maximum clot firmness (MCF), area under the curve (AUC), maximum 
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CT and CFT were prolonged by lowering temperature and pH independently 
and very prolonged (CT=265.4 seconds delay/ CFT=321.6 seconds delay) 
when both hypothermic and acidotic conditions were combined (Table 4.8.). 
 
Hypothermia and acidosis alone did not induce any significant changes on the 
Alpha angle nor on the MCF, but when combined, Alpha dropped down to 41° 
and the amplitude of the MCF decreased by 11.2mm.  
The AUC calculated by the software only demonstrated a significant decrease 




The correlation between the results from the whole blood NATEM® assay and 
the ones performed on PPP with the EXTEM® assay were good. 
 
All of the parameters used in both Assays (CT, CFT, Alpha, and MCF) were 
completely concordant and confirmed once again that when acidosis and 
hypothermia are combined haemostasis is affected and a bleeding pattern is 
observed in vitro.  
This was also registered when looking at AUC, which was decreased at 
critical conditions. This close agreement suggests that the effects are plasma 
based rather than having a cellular influence in this test. 
 
These findings are in agreement with previously published data; a study of 
Thromboelastometry and acidosis (Engström et al. 2006) and a study on 
hypothermia effects on coagulation using thromboelastometry (Kheirabadi et 
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5. INTRODUCTION 
 
Having characterized in vitro the effects of hypothermia and acidosis on the 
Haemostatic process, it is necessary to establish the response of normal 
plasma samples for any given temperature and pH. These reference ranges 
could then be used to interpret the haemostasis in clinically compromised 
individuals. This study was performed to derive for any given temperature and 
pH. 
 
The CAT assay was used to derive these reference ranges. First, to set up 
reference ranges at different temperatures and secondly, to produce 
reference ranges at different pH values and ultimately, the reference ranges 
for combined hypothermic and acidotic conditions.  
 
5.1. REFERENCE CAT RANGES OVER THE TEMPERATURE RANGE 
31°C - 41°C 
 
To understand the effects of temperature on the CAT assay, 20 samples from 
healthy volunteers were assayed at different analytical temperatures. The 
temperature range was based on physiological temperatures that could be 
observed during trauma or illness. 
 
Three CAT parameters were examined on this study, namely: 
Endogenous thrombin potential (ETP), lag time (LAG) and the peak height of 
the CAT curve (PEAK).  
The temperatures studied ranged from mild hypothermia (31°C, 33°C and 
35°C) to moderate/severe hyperthermia (39°C and 41°C). 
The aim of this study was to establish the CAT assay ranges for healthy 
individuals at these different temperatures. The results obtained from this 
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5.1.1. Results using PPP 
5.1.1.1. Endogenous Thrombin Potential (ETP) 
The table below shows the amount of thrombin produced at any given 
temperature (Table 5.1.). 
 




31°C 2680 331 
33°C 2188 215 
35°C 1939 179 
37°C 1792 155 
39°C 1425 179 
41°C 1138 118 
 
Table 5.1. The effect of temperature on endogenous thrombin potential (ETP).  
 
The ETP increased with hypothermia, reaching a mean value of 2680 nmol of 
thrombin at 31°C with a p-value <0.01 compared to 37°C (Table 5.4). With 
hyperthermia, ETP values dropped to 1138 nmol of thrombin produced at 
41°C (p-value <0.01) compared to 37°C (Table 5.4). 
 
The results presented in Fig.5.1.demonstrated how the assay temperature 


























Fig.5.1. The effect of temperature on endogenous thrombin potential (ETP).  
Results expressed as the mean +/- SD. 
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5.1.1.2. Lag time (LAG)  
The mean lag time observed at normal body temperature was 6.27 min. This 
lag time increased as the temperature went down (LAG = 8.41 min. at 31°C, 
p-value <0.01 compared to 37°C (Tables 5.2. and 5.4.)) (Fig.5.2.). On the 
other hand, the lag time observed under hyperthermic conditions shortened 
by more than a minute at 41°C (LAG = 5.03 min at 41°C, p-value <0.01 









31°C 8.41 0.89 
33°C 7.49 0.84 
35°C 6.73 1.2 
37°C 6.27 1.42 
39°C 6.06 1.59 
41°C 5.03 0.67 
 



























Fig. 5.2. The effect of temperature on Lag times.  
Results expressed as the mean +/- SD. 
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5.1.1.3. Peak height (PEAK) 
The peak height results obtained followed a similar trend to the ETP values 
(Table 5.3.) (Fig. 5.3.). PEAK values in hypothermic conditions were much 
higher than those noted under hyperthermic conditions. However, the only 








31°C 216 54.8 
33°C 201.3 40.7 
35°C 200 38.5 
37°C 173.7 31.4 
39°C 148.5 50.4 
41°C 126.1 35.1 
 





























Fig. 5.3.  The effect of temperature on Peak. 
Results expressed as the mean +/- SD. 
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31 -2.14 P<0.01 -3.199 -1.07 
33 -1.22 P<0.01 -2.280 -.15 
35 -0.46 NS -1.522 .60 
39 0.21 NS -.849 1.27 




31 -887.73 P<0.01 -1078.09 -697.36 
33 -395.67 P<0.01 -586.03 -205.30 
35 -146.53 NS -336.89 43.83 
39 367.68 P<0.01 177.32 558.04 




31 -42.35 P<0.05 -81.49 -3.2 
33 -27.62 NS -66.76 11.52 
35 -26.32 NS -65.46 12.82 
39 25.18 NS -13.96 64.32 
41 47.59 P<0.01 7.93 87.24 
 
Table 5.4. Statistical data on reference CAT ranges for the temperature 
studies.This table shows the comparison of data obtained at 37°C with data 
obtained at 31°C,33°C, 35°C, 39°C and 41°C respectively. P values of <0.05 
were considered significant (in blue). Non significant p values are expressed 
as NS (in red). Abbreviations: endogenous thrombin potential (ETP). 
 
 
5.2. REFERENCE CAT RANGES OVER THE pH range 6.9-7.5 
 
 
This study also examined the effects that different pH values exerted on the 
CAT Assay. Samples from healthy volunteers were assayed. The pH range is 
based on physiological values that the human body can sometimes 
experience in trauma or illness (Lier et al., 2008; Demirjian et al., 2008). 
 
Three CAT parameters were looked at on this study, namely:  
Endogenous thrombin potential (ETP), lag time (LAG) and the peak height of 
the CAT curve (PEAK).  
 
Four different pH values were used: pH 6.9, pH 7.1, pH 7.35 and pH 7.5.  
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The aim of this study was to establish the CAT assay ranges for healthy 
individuals at these different pH values.  The results obtained from this study 
could be used to standardise results from patients. 
 
5.2.1. Results on PPP 
 
5.2.1.1. Lag Time 
Acidosis increased the lag time by almost 2 minutes (8.225 min. at pH 6.9) 
(p<0.05) (Table 5.8.), compared with the lag time at physiological pH (6.227 







pH 6.9 8.225 1.31 
pH 7.1 7.087 0.7 
pH 7.35 6.277 1.93 
pH 7.5 5.29 1.27 
 
Table 5.5. The effects of pH on lag time results. Results are expressed as 






















Fig. 5.4.  The effect of pH on lag time variations. Results expressed as mean 
±SD of 10 estimations. 
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5.2.1.2. Endogenous Thrombin Potential (ETP) 
The table below (Table 5.6) shows the amount of thrombin produced at 







pH 6.9 1984.8 684.3 
pH 7.1 1935.2 592.7 
pH 7.35 1789.8 570.1 
pH 7.5 1429.5 496.2 
 




At a pH of 6.9 ETP increased to a maximum value of 1984.8nmol. 
Conversely, when the pH was alkaline, the ETP decreased down to 1429 
nmol (pH 7.5) (p<0.05, compared to pH 7.35) (Table 5.8.). 
The results (Fig. 5.5.) show how the assay pH affected the ETP using PPP 
























Fig. 5.5. The effect of pH on ETP. Results expressed as mean ±SD. 
Abbreviations: endogenous thrombin potential (ETP). 
 
 
69 CHAPTER V: REFERENCE RANGES 
5.2.1.3. Peak height (PEAK) 
 
As the following Table shows (Table 5.7.), peak height of the CAT curve was 
not affected by the assay pH. The PEAK remained almost identical at the four 








6.9 179.8 68.6 
7.1 174.3 80.2 
7.35 173.7 61.1 
7.5 177.9 76.7 
 





















Lag Time 7.35 
6.9 -1.95 P<0.05 -3.61 -0.29 
7.1 -0.81 NS -2.47 0.85 
7.5 0.99 NS -0.67 2.65 
ETP 7.35 
6.9 -194.9 NS -495.67 105.85 
7.1 -145.35 NS -446.11 155.41 
7.5 360.36 P<0.05 59.59 661.12 
Peak 7.35 
6.9 -6.13 NS -70.64 58.38 
7.1 -0.59 NS -65.10 63.92 
7.5 -4.19 NS -68.70 60.32 
 
 
Table 5.8. Statistical data on reference CAT ranges for the pH studies. This 
table shows the comparison of data obtained at pH 7.35 with pH 6.9, pH 7.1 
and pH 7.5 respectively. P values of <0.05 were considered significant (in 
blue). Non significant p values are expressed as NS (in red). Abbreviations: 
endogenous thrombin potential (ETP). 
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5.3. REFERENCE RANGES AT pH 7.1 
 
 
The reference ranges presented in this chapter could be used as the 
reference to be compared when measuring any given sample with the CAT 
Assay.  
 
In the next chapter, samples obtained from Addenbrooke’s Hospital Intensive 
Care Unit patients were used and tested. 
 
To be able to compare the use these normal ranges in the ICU set of 
samples, a combination of assay temperature and assay pH were required. 
Based on the average conditions of the 10 ICU samples tested, it was clear 
that ranges based upon a fixed pH of 7.1 combined with varying degrees of 
acidosis was required (Table 5.9.). 
The table below shows the reference ranges set for hypothermia (temperature 
from 31°C to 37°C) and pH 7.1(Table 5.9.). 
 
 Lag time at pH 7.1 MEAN (min) SD 
31°C 8.846 0.62 
33°C 8.063 0.66 
35°C 7.854 0.69 
37°C 7.087 0.73 
ETP at pH 7.1 MEAN (nmol) SD 
31°C 2543 227.7 
33°C 2206 251.2 
35°C 2130 202 
37°C 1935 121.8 
PEAK at pH 7.1 MEAN (nmol.min) SD 
31°C 190.2 39.3 
33°C 182.9 48.1 
35°C 175.2 53.5 
37°C 174.3 65.7 
 
Table 5.9. Lag time, ETP and peak results for hypothermia and pH 7.1. 
Abbreviations: endogenous thrombin potential (ETP). 
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As noted previously, parameters such as lag time (Fig. 5.6.) and ETP (Fig. 
5.7.) were much higher during hypothermic conditions at pH 7.1. The peak 
heights did not experience significant changes with the drop in temperature at 





















































Fig. 5.7.  ETP variations with temperature at pH 7.1. Results expressed as 
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6. STUDIES ON ICU SAMPLES 
 
 
This chapter looks at data obtained from 17 patients who were admitted to the 
Intensive Care Unit at Addenbrooke’s Hospital. Consent was obtained for 
sample testing in the laboratory with all the patient details being anonymized. 
 
Samples were collected in S-monovette® 9NC (PFA). These tubes were 
chosen because they contain a buffer which will preserve the original pH of 
the sample. Corn Trypsin Inhibitor (12.66 µl CTI) was also added to each tube 
before use. This gave a final concentration of 1.45µmol/L of CTI. 
 
The selection process used for the 17 patients in the ICU was based on two 
parameters used on the APACHE Scoring System: Temperature and pH. 
 
The requirements were simple, patients had to experience some degree of 
hypothermia and/or acidosis when admitted to the ICU and when the samples 
were taken. 
 
The patients who fitted these criteria were selected and the temperature and 
pH of the patient was noted at the time of bleeding. 
 
Out of the 17 patients received from ICU, only 10 were finally used due to 
heparin contamination. The heparin contaminated samples gave a completely 
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A full description of the temperatures and pH of the 10 patient samples used 




ICU SAMPLES Temperature pH 
1 36.1 7.12 
2 35.4 7.21 
3 35.7 7.15 
4 36.1 7.04 
5 35.9 7.22 
6 34.5 7.06 
7 34.8 7.1 
8 36 7.15 
9 35.8 7.14 
10 35.6 7.13 
Mean 35.59 7.132 
SD 0.546606 0.057116 
 
Table 6.1 Temperature and pH of ICU samples. 






Samples were tested as soon as they arrived from ICU using the CAT Assay. 
PPP and PRP were prepared from whole blood. 
To study the effects of hypothermia and acidosis on the patient’s clotting 
profile, two parallel assays were designed: 
 
a) CAT assay of patient’s PPP and PRP at its original temperature and pH. 
b) CAT assay of patient’s PPP and PRP at a corrected analytical temperature 
(37°C) and physiological pH (7.35). 
 
6.1.1. PRP – CAT 
Table 6.2 shows the CAT parameters for the two different assays described 
above (Table 6.1). The results are presented as the average values of the 
patient results. pH was always measured at a room temperature. For 
correction or change of sample pH, sodium hydroxide (1.52M) or lactic acid 
(1.16M) was used. Assay temperatures were set on the analyzer. 
 
 













Mean 10.65 1910 107 19.48 65.1 
SD 1.5 156.9 10.1 1.47 6.3 
ICU PRP 











Mean 5.44 1684.1 90.3 14.36 37.9 
SD 0.99 97.7 4.71 1.52 3.38 
 
Table 6.2. CAT results for ICU with PRP. Abbreviations: intensive care unit 
(ICU), platelet rich plasma (PRP), endogenous thrombin potential (ETP), time-
to-peak (TT PEAK). 
 
 
When comparing the average values of the ICU patients in their original 
hypothermic acidotic state, with the values measured, when body temperature 
and pH were restored back to standardised conditions (T=37°C, pH=7.35) a 
number of key changes were observed: 
i. A marked decrease in the lag time from 10.65 min to 5.44 min was 
seen when temperature and pH were standardised. 
ii. The ETP decreased from 1910 to 1684 nmol of thrombin. 
iii. The peak was slightly lower. 











Interval of the 
Difference 
Lower Upper 
Lag time (min) 9.136 P<0.01 5.21 4.01 6.41 
ETP (nmol) 3.868 P<0.01 226.1 103.3 348.89 
PEAK (nmol.min) 4.756 P<0.01 16.69 9.09 24.28 
TT PEAK (min) 7.641 P<0.01 5.12 3.71 6.52 
Start tail (min) 12.00 P<0.01 27.18 22.42 31.94 
 
Table 6.3: Independent Samples t-test on the data in table 6.2. P values of 
<0.05 were considered significant (in blue).  Abbreviations: platelet rich 
plasma (PRP), endogenous thrombin potential (ETP). 
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To visualize how this temperature and pH correction affected the CAT, a CAT 
profile (obtained from the average values of the 10 samples) was derived for 






Fig. 6.1. PRP CAT curves for the original and corrected temperature and pH 



















Mean 10.77 1629.7 144.6 15.5 50.2 
SD 0.78 181.4 20.9 2.6 4.24 
ICU PPP 











Mean 4.84 1425.4 111.3 8.34 33 
SD 0.63 136.8 16.1 0.61 6.1 
 
Table 6.4. CAT results for ICU using PPP. Abbreviations: intensive care unit 
(ICU), platelet poor plasma (PPP), endogenous thrombin potential (ETP), 








0 10 20 30 40 50 60 70 80 


















77 CHAPTER VI: INTENSIVE CARE UNIT SAMPLES 
 
 
Table 6.4 shows the different CAT parameters for assays performed under 
standardised conditions and the original hypothermic and acidotic conditions. 
 
When comparing the average values of the ICU patients in their original 
hypothermic acidotic state with the values measured (as done before with the 
PRP parameters ), various important differences were again observed. These 
are summarized below: 
 
i. The Lag Time dropped dramatically from 10.77 min down to 4.84 min. 
ii. The ETP decreased slightly from 1629.7 to 1425.4 nmol of Thrombin. 
iii. The Peak was 30nmol/min lower than under standardised conditions. 













Interval of the 
Difference 
Lower Upper 
Lag time (min) 18.65 P<0.01 5.93 5.26 6.6 
ETP (nmol) 2.84 P<0.01 204.29 53.34 355.23 
PEAK (nmol.min) 3.98 P<0.01 33.28 15.73 50.82 
TT PEAK (min) 8.52 P<0.01 7.21 5.32 9.09 
Start tail (min) 7.30 P<0.01 17.2 12.25 22.15 
 
Table 6.5: Independent Samples t-test on the data in table 6.4. 
 P values of <0.05 were considered significant (in blue). Abbreviations: 
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The figure below demonstrates clearly how the temperature/pH correction 




























Fig. 6.2. PPP CAT curves for the original and corrected temperature and pH 







6.2. ICU CAT results compared to CAT Reference ranges 
 
The three most important parameters of the CAT Assay (Lag time, ETP and 
peak) were chosen for the comparison of the ICU results with the reference 
ranges obtained in the previous chapter. 
 
Two different comparisons were performed: 
a) ICU results against reference ranges at 35°C and a pH of 7.1. 
b) ICU results against reference ranges at 37°C and a pH of 7.35. 
 
The graphs below show the a) and b) comparisons for lag time (Fig. 6.3), for 
ETP (Fig. 6.4) and the peak height (Fig. 6.5). 
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6.2.1. Lag Time. ICU against Reference ranges 
 
The lag times of the ICU samples for temperature 35°C and pH 7.1 were 
much longer than those obtained in healthy volunteers. 
 
When measured under standardised conditions (37°C/pH 7.35), the ICU 
sample lag times were much closer, if not shorter in some cases, to the 
reference ranges. 
 
These results obtained at a 35°C and pH 7.1 indicated that ICU samples are 
hypo-coagulable, but when conditions were standardised, the pattern 

































Fig.6.3. ICU results against reference ranges for lag time. Reference values 
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6.2.2. ETP. ICU against Reference ranges 
 
The same pattern of results was seen at 35°C /pH 7.1 as seen at 37°C /pH 
7.35. ICU ETP seems to be closer to the reference ranges at 37°C /pH 7.35 
than at 35°C /pH 7.1, where values seem to be more dispersed. In both 







































Fig.6.4. Reference ranges against ICU results for ETP values. 
Reference values are expressed as the mean +/- SD. 
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6.2.3. Peak. ICU against Reference ranges 
 
The peak height of the ICU samples at 35°C/pH 7.1 was similar to the 
reference range values under the same conditions. When tested at 37°C/pH 
7.35 ICU peak values were below reference range. This indicates that ICU 
samples have a hypo-coagulable tendency when measured at standardised 











































Fig.6.5. Reference ranges against ICU results for peak values. Reference 
values are expressed as the mean +/- SD. 
 
 
TEMPERATUR  (°C)/pH 
 
 






Test    
  35°C/pH 7.1 




















-1.68 NS -30.62 -70.30 9.05 
 
Table 6.6. t-test for comparison of means between ICU samples and healthy 
volunteers samples at 35°C and pH 7.1.  






























-4.91 P<0.01 -62.40 -89.08 -35.71 
 
Table 6.7. t-test for comparison of means between ICU samples and healthy 
volunteers samples at 37°C and pH 7.35. 
 Abbreviations: endogenous thrombin potential (ETP). 
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6.3. HEPARIN SAMPLE REMOVAL 
 
 
Due to problems with heparin contamination, some of the samples received 
from the ICU could not be measured on the CAT and therefore, the data was 
lost and more importantly a valuable sample was wasted. 
 
Heparin is an anticoagulant with several effects on the coagulation cascade. 
The most important one is the increase in the thrombin inhibitory potency of 
ATIII by 1000 fold (Blauhut et al., 1980). ATIII inhibits thrombin + FIXa, FXIa & 
FXIIa. 
Heparin contamination prolongs the APTT, to a lesser extent the PT and also 
affects thrombin generation on the CAT Assay, which is much more sensitive 
than traditional coagulation tests on detecting heparin in the sample (Gatt, A. 
et al., 2008). 
 
A possible technique that could solve this would be the use of an anti-heparin 
agent. This could be applied to any contaminated sample to neutralize the 
effects of the heparin. 
 
Hepzyme is a heparinase, which neutralizes therapeutic or contaminant 
heparin in clinical specimens (Forte et al., 2000). 
 
Adding Hepzyme to a non heparin contaminated sample did not affect its 
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Normals PT(seconds) APTT (seconds) 
1 12.9 27.1 
1+ Hepzyme 12.9 27.1 
2 12.1 23.7 
2 + Hepzyme 12.2 23.9 
3 13.3 26.8 
3+ Hepzyme 13.4 27.2 
4 12.1 29.7 
4+ Hepzyme 12.4 28.7 
5 11.9 27.3 
5+ Hepzyme 12.3 27.6 
6 11.5 25.6 
 6+ Hepzyme 11.7 25.6 
7 12.3 26.6 
7+ Hepzyme 12.6 26.0 
8 13.1 28.3 
8+ Hepzyme 13.1 28.5 
9 12.4 27.3 
9+ Hepzyme 12.7 26.5 
10 12.7 26.6 
10+ Hepzyme 12.9 26.6 
 
Table 6.8. Clotting Screens for 10 normal samples with and without Hepzyme. 
Abbreviations: prothrombin time (PT), Activated Partial Thromboplastin Time 
(APTT). 
 
Hepzyme is not only effective with heparin but also with Low molecular weight 




Table 6.9. Effects of Heparin with or without Hepzyme on the PT and APTT. 
Abbreviations: platelet poor plasma (PPP), prothrombin time (PT), Activated 
Partial Thromboplastin Time (APTT). 
Type of Heparin Anti-Xa Level PT(seconds) APTT (seconds) 
Normal PPP 0.00 12.9 36.0 
PPP + Hepzyme 0.00 13.3 36.8 
PPP +Heparin 1.02 14.4 201.9 
PPP+Heparin + Hepzyme 0.00 13.1 33.8 
PPP+Fragmin 1.00 17.0 171.2 
PPP+Fragmin + Hepzyme 0.00 13.5 39.0 
PPP+Tinzaparin 1.02 19.4 182.9 
PPP+Tinzaparin + Hepzyme 0.00 13.5 36.2 
PPP+Clexane 1.09 16.4 117.6 
PPP+Clexane + Hepzyme 0.02 13.8 37.7 
PPP+Danaparoid 1.07 15.7 119.1 
PPP+Danaparoid + Hepzyme 0.00 13.6 38.4 
PPP+Atrixa >1.50 15.1 58.6 
PPP+Atrixa + Hepzyme 0.12 14.1 47.2 
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The CAT is an assay that is very sensitive to heparin. It is able to detect 
minimal residues of heparin in a sample and can be used to monitor the use 
of any anticoagulant in an accurate manner (Gatt et al, 2008). 
 
By using the CAT it was possible to visualize how Hepzyme could neutralize 











Normal PPP 2.89 1466 104.51 8.24 
PPP + Hepzyme 2.89 1335.5 90.08 8.07 
PPP+Heparin 10.91 42.5 2.21 18.43 
PPP+Heparin + Hepzyme 2.56 1411.5 103.96 7.40 
PPP+Fragmin 7.23 141 6.34 15.08 
PPP+Fragmin + Hepzyme 2.72 1354.5 97.46 7.90 
PPP+Tinzaparin 8.24 60.5 2.63 19.43 
PPP+Tinzaparin + Hepzyme 2.89 1393.5 101.54 7.74 
PPP+Clexane 6.07 180.5 8.80 13.75 
PPP+Clexane + Hepzyme 2.89 1299.5 93.42 8.24 
PPP+Danaparoid 7.57 123.5 5.19 16.09 
PPP+Danaparoid + Hepzyme 3.23 786 50.35 11.08 
PPP+Atrixa 13.08 101 3.41 33.63 
PPP+Atrixa + Hepzyme 2.89 1173 84.9 8.40 
 
Table 6.10.  Heparin with or without Hepzyme using the CAT. Abbreviations:  
platelet poor plasma (PPP), endogenous thrombin potential (ETP), time to 
peak (TT Peak) 
 
To illustrate how Hepzyme neutralizes Heparin, the following graphs show the 
CAT assay run on samples containing different types of Heparin with and 































Figure 6.7. The effects of Tinzaparin in the presence & absence of Hepzyme 






























































































































Figure 6.9. The effects of Clexane in the presence & absence of Hepzyme on 

















Figure 6.10. The effects of Danaparoid in the presence & absence of 




The above experiments show that Hepzyme treatment could be used in the 
ICU patients for assessment of samples using CAT under hypothermia and 
acidosis and would enable meaningful results on a greater proportion of 
patients (only 10/17 (59%) can be used in the absence of heparin 
neutralisation). 
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7. INTRODUCTION 
Massive bleeding in patients with major trauma is the most common cause of 
in-hospital mortality during the first 48 hours. Following admission the highest 
mortality occurs in patients with hypothermia, acidosis, and coagulopathy. 
(Patt et al, 1988). This combination is commonly referred to as the "lethal triad 
of trauma." Although the lethal triad has been recognized for a decade, the 
underlying mechanisms related to the development of coagulopathy are not 
fully understood.  
Clotting Screens, such as the APTT, PT, and thrombin time, are prolonged 
when assays are performed at patient temperature in hypothermic patients or 
plasma cooled in vitro.  
 
7.1 Activated partial thromboplastin time and prothrombin time 
The PT and APTT assays are often used as screening tests and surrogate 
markers of coagulation factor levels in trauma settings. Testing the PT and 
APTT in this study under hypothermic and acidotic conditions showed and 
confirmed what has already been described by several groups around the 
world, i.e. that under hypothermic and /or acidotic conditions the PT and 
APTT experience a time prolongation (Breen et al., 1988; Reed, 1990; Gubler 
et al, 1994; Armand et al., 2003). 
Hypothermia significantly prolonged the PT by more than 5 seconds (p<0.01) 
and the APTT for almost 2 seconds on PPP (p<0.01), (Table 4.1.). PRP APTT 
was also prolonged under hypothermic conditions for more than 8 seconds 
(p<0.01), (Table 4.2.). Acidosis prolonged the PT for almost 3 seconds and 
the APTT for more than 36 seconds on PPP (Table 4.1.). PRP APTT was also 
delayed by 29 seconds (Table 4.2.). These results showed that either 
hypothermia or acidosis have an effect on the coagulation process in vitro, by 
delaying PT and APTT clotting times.  
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Hypothermic and acidotic conditions alone significantly prolonged PT and 
APTT. When hypothermic and acidotic conditions were combined, the 
PT/APTT time delays were even longer, suggesting a possible cumulative 
effect of the two conditions over the coagulation process. PT was prolonged 
by more than 9 seconds (p<0.01) and the APTT by 58 seconds on PPP 
(p<0.01) under the combined conditions of acidosis and hypothermia (Table 
3.1.). In addition, the PRP APTT showed a delay of 44 seconds (p<0.01), 
(Table 3.2.). 
The progressively prolonged PT and APTT times in vitro under hypothermic 
and/or acidotic conditions suggest that unless temperature and/or pH are 
corrected a bleeding tendency will be observed in vivo.  
 
7.2 Calibrated Automated Thrombogram  
As the CAT assay is a fluorometric rather than a clot based technique, it is 
possible to continue with the measurement after the clot is formed. This is an 
important difference between the CAT and the standardised clotting screens 
such as PT and APTT.  When clot formation occurs the clot tests stop 
measuring but for the CAT assay this is just the beginning of the assay which 
is called lag time. After the lag time the system will carry on with the 
measurement until the sample runs out of thrombin (Section 1.7.1.). 
The use of two different types of plasma samples, namely PPP and PRP 
demonstrated that some parameters were consistent and behaved equally 
while others did not correlate nor follow any particular trend. The lag time and 
the ETP followed the same trend for both types of plasma samples. lag time 
on PPP, however was prolonged under hypothermic conditions by 0.46 
minutes (The lag time at 31°C /pH 7.35 was 8.37 minutes (Table 4.3.)). ETP 
on PPP increased under hypothermic conditions from 1777nmol to 2638nmol 
of thrombin (Table 4.3.), whilst peak, time-to-peak and velocity did not show 
any correlation between PPP and PRP sample measurements. 
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With the CAT methodology there seems to be a disparity between some of 
the results obtained. In general, it seems that some parameters (lag time and 
ETP) are affected by both conditions on its own but when both are combined 
(hypothermia + acidosis) there is a cumulative effect which exaggerates the 
changes. Lag time experienced a 2.55 minutes delay on PPP (Table 4.3.) and 
2.3 minutes delay on PRP (Table 3.5). ETP increased by 1075nmol of 
thrombin (Table 4.3.) and 845.2 nmol of thrombin (Table 3.5) on PPP and 
PRP respectively. 
The observed delays in lag time, which correlated with worsening conditions, 
supports the findings of the standard laboratory assays and previous literature 
(Tables 4.3 & 4.5. for CAT lag times and tables 4.1 & 4.2 for PT/APTT). The 
data started to diverge from the published perception of hypocoagulability 
based upon laboratory data when the ETP was examined.  
The ETP began to increase when temperature was reduced (861nmol on PPP 
and 435.55nmol on PRP) (Tables 4.3. and 4.5.)) or pH decreased (208nmol 
on PPP and 276.2nmol on PRP) (Tables 4.3. and 4.5.)). The cumulative effect 
of acidotic and hypothermic conditions was also observed in the overall ETP 
(1075nmol on PPP and 845.2nmol on PRP) (Tables 4.3. and 4.5.)). These 
particular observations do not fit with any of the previously published 
literature, where a hypocoagulable state is always seen under abnormal 
conditions, such as hypothermia and acidosis.  
These CAT results under abnormal conditions suggest that in spite of having 
a delayed lag time, which will indeed present as a bleeding risk to the patient, 
once the thrombin burst occurs elevated levels of thrombin will be generated. 
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7.3 ROTEM 
Generally speaking, the results obtained from the ROTEM® methodology 
indicate a clear tendency for a coagulopathy in critical conditions, namely 
acidosis and hypothermia. The times to clot were very prolonged, the clot 
formation rates were decreased and clot stability worsened.  
There was a close similarity between the results from the whole blood 
NATEM® Assay and the ones performed on the PPP with the EXTEM® assay 
was good (i.e. increments on CFT were observed with both assays when 
hypothermic and acidotic conditions were used). CFT=245% increase on 
EXTEM® (Table 4.7.) and CFT=207% increase on NATEM® (Table 4.8.). 
All of the measured parameters confirmed that when acidotic and hypothermic 
conditions were combined that haemostasis was affected and a 
hypocoagulable picture was observed in vitro, with a delay in clot formation 
and a weaker clot formed (i.e. MCF decreased to 43.6 mm from 54.8mm 
under physiological conditions on the NATEM® assay (Table 4.8)).  
AUC values, which were decreased at critical conditions (i.e. The 37/7.35 
AUC was 5494.2nmol of thrombin compared to the 31/6.9 AUC, which was 
4460.4nmol of thrombin on the NATEM® assay (Table 4.8)) were also 
consistent with this conclusion. 
These findings are in agreement with previously published data on acidosis 
(Engström et al. 2006) and hypothermia effects on coagulation using 
Thromboelastometry (Kheirabadi et al., 2007; Dirkmann D et al., 2008; Rohrer 
et al.,1992). 
It is interesting to note that the hypercoagulable findings of the CAT assay are 
not reflected in this “global test” of haemostasis. This is presumably due the 
nature of the end point detection. When fibrin polymerisation is used as the 
endpoint as in the ROTEM the effect of prolonged thrombin generation does 
not influence the assay. A similar finding to that experienced in the PT and 
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APTT. It is only when assess thrombin as the end-point that the anomaly 
becomes evident. 
 
7.4. REFERENCE RANGES 
By studying how samples obtained from healthy volunteers would perform 
under different conditions of temperature and/or pH it is possible to establish 
their CAT assay ranges. These ranges could be used as standards for future 
comparisons with any given sample at any specific condition. 
The CAT assay demonstrated that hypothermia and acidosis alone induced a 
hypocoagulable pattern initially, until the thrombin burst occurs. Then the 
thrombin generated, as defined by the ETP, becomes higher as the conditions 
worsen. In vitro analysis using healthy volunteers demonstrated that 
hypothermic and acidotic conditions produced a cumulative effect when used 
in combination. 
Higher body temperatures were also tested in vitro with the CAT assay. This 
showed the opposite effect of hypothermia. The lag times shortened as the 
temperature was increased (i.e. Lag time at hyperthermia shortened by more 
than a minute at 41°C; LAG = 5.03 min at 41°C, (p<0.01) compared to 37°C 
(Table 5.4.)) and the ETP became lower as the assay temperature rose. 
The third parameter used to establish the reference ranges was the peak 
height of the CAT curve. The peak showed some correlation with the ETP but 
the changes produced by the different temperatures and pHs were not 
significant. The only significant peak values observed were at 31°C (p<0.05) 






93 CHAPTER VII: DISCUSSION 
7.5. ICU SAMPLES 
Acidosis, hypothermia, and coagulopathy have been identified as the lethal 
triad for patients admitted to ICU. Recent studies report most severely injured 
patients to be coagulopathic on admission and that traditional massive 
transfusion practice grossly underestimates needs (Gonzalez et al., 2007). 
Management of coagulopathy is based on blood component replacement 
therapy. However, there is a limit to the level of haemostasis that can be 
restored and that can be predictive of mortality (Spahn et al, 2005). 
The present study showed that standard investigations in a haemostasis 
laboratory will not be suitable for any patient who has body hypothermia or 
acidosis. Laboratory tests will underestimate the patient’s real condition due to 
default temperature and pH correction when analyzed.  
It is common practice that coagulation analyzers are set to a standard 
temperature of 37°C, and this will consequently not take into account the 
original body temperature of the patient. Sample buffering will also result in 
tests being analyzed at a physiological body pH without allowance for the 
patient’s original blood pH. 
By comparing the CAT results obtained from the ICU patients in their original 
hypothermic and acidotic state, with the CAT results from these patients with 
corrections applied for temperature and pH, it was possible to see how these 
corrections affected the results. 
The results changed dramatically with the temperature and pH corrections. 
The lag times shortened by more than a half, the ETP decreased by around 
300nmol.min  of thrombin, the peak was slightly lower and the time-to-peak 
was also reduced in magnitude (Table 6.2.). Temperature and pH corrections 
resulted in results that significantly different. At this point, interpretation of 
these results is critical for the diagnosis but by applying temperature and pH 
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7.5.1. ICU CAT results compared to CAT Reference ranges 
To compare a CAT result from any apparently healthy person with that of an 
ICU patient two possible approaches were chosen. First, they could be 
compared at standardised conditions or second, they could be compared at 
the original ICU patient temperature and pH. 
Measuring the CAT profile at a temperature of 35°C and a pH of 7.1 (35°C 
/pH 7.1) indicated that ICU samples demonstrated hypo-coagulable profile, 
but when conditions were standardised, the pattern seems to show an 
opposite situation.  
Lag times obtained from ICU patients at 37°C /pH 7.35 suggested a hyper-
coagulable state.  ETP seems to be closer to the reference range at 37°C /pH 
7.35 than at 35°C /pH 7.1. In both cases, ICU patients tended to have a lower 
ETP than healthy volunteers. The peak height of the ICU patients at 35°C /pH 
7.1 was within the reference range observed under the same conditions. 
When tested at 37°C /pH 7.35 ICU peak values were below the lower limit of 
the reference range. This indicates that ICU samples have a hypo-coagulable 
tendency when measured at corrected pH and temperature but seem to be 
“normal” when tested at their original conditions. 
The role of hypothermia and acidosis during sample analysis, would indicate 
that establishing reference ranges for any given temperature or pH could be 
beneficial for the diagnosis and management of ICU patients. 
 
7.6. Problem solving 
7.6.1. pH 
After performing hundreds of measurements during this project on pH 
modified samples, it was possible to conclude that pH manipulation, if not 
done carefully, could completely alter the results. The main problem 
encountered when modifying the pH was coagulation activation. To avoid 
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sample coagulation cascade activation, a duplicate sample had always to be 
used for pH manipulation to allow the amount of base or acid added to be 
calculated. The same volume could then be added to another sample for 
experimental purposes. By doing this, experimental samples were never 
exposed to the pH meter glass probe, which was found to be a possible cause 
of activation of the plasma (Table 3.1.).  
7.6.2. Cold activation 
To avoid the freezing and thawing effects (Norda et al., 2008; Palmer et al., 
1982), this study was performed on fresh samples. The only way to achieve 
this was by bleeding the healthy volunteers each time before analysis was 
performed and analysing the samples from ICU at the time of collection. 
 
7.6.3. HEPARIN 
Due to problems with heparin contamination, some of the samples received 
from the ICU could not be measured on the CAT analyser and therefore, the 
data was lost and more importantly valuable samples were wasted. 
Heparin is an anticoagulant with several effects on the coagulation cascade. 
The most important one is the increase in the thrombin inhibitory potency of 
ATIII by 1000 fold (Blauhut et al., 1980). ATIII inhibits thrombin + FIXa, FXIa & 
FXIIa. Heparin contamination prolongs the APTT, and to a lesser extent the 
PT and also affects thrombin generation as measured by the CAT assay, 
which is much more sensitive than traditional coagulation tests to heparin 
within the sample (Gatt et al., 2008). 
A possible technique adaptation that could remove this problem would be the 
use of an anti-heparin agent. This could be applied to any contaminated 
sample to neutralize the effects of the heparin. Hepzyme is a heparinase, 
which neutralizes therapeutic or contaminant heparin in clinical specimens 
(Forte et al., 2000). Adding Hepzyme to a non heparin contaminated sample 
however did not affect its clotting screen (PT or APTT), (Table 6.8). 
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The CAT procedure is an assay that is very sensitive to Heparin. It is able to 
detect minimal residues of heparin in a sample and can be used to monitor 
the use of any anticoagulant in an accurate manner (Gatt et al, 2008). 
By using the CAT procedure it is possible to visualize how Hepzyme can 
neutralize the effects of different types of heparins (Table 6.10.). Data from 
this study showed that Hepzyme can be effective against several types of 
heparinoids, such as heparin, Fragmin, Tinzaparin, Clexane, Danaporoid and 
Atrixa (Table 6.10.). 
 
7.7. CONCLUSIONS 
Both hypothermic and acidotic conditions contribute to coagulopathy, and that 
their combination has additive effects. 
CAT results produced under hypothermic and/or acidotic conditions suggest 
that in spite of having initially a delayed lag time, once the thrombin burst 
occurs it will generate more thrombin which will increase the overall ETP. 
Therefore once the initial lag time has passed there is a potential 
hypercoagulable situation. 
Traditional clotting screens are not the most suitable assays to be performed 
for the study of coagulation in critical care patients, because they only 
measure the initiation of the coagulation process.   
Global assays, such as thromboelastometry and CAT are better suited for the 
clinical investigation in the ICU but an understanding of the nature of the end-
point of the tests is essential when interpreting the results. After clot formation 
the measurement continues with global assays and valuable information is 
obtained, such as clot firmness and stability or how much thrombin is 
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Although these standard clotting tests are performed at 37°C and 
physiological pH, in vitro testing of any given sample should ideally be 
performed at the patient’s own body temperature and pH as well as under the 
corrected conditions. This will give a picture of what is happening now 
compared to what will happen when the hypothermia/acidosis is corrected. 
 
7.8. Future work 
This study has shown the effects of hypothermia and acidosis on the 
haemostatic process and how different assays can give results that not 
always follow the same pattern. 
To achieve a better understanding of how these abnormal conditions affect 
coagulation, it would be interesting to look at other coagulation factor levels 
during hypothermia and with acidosis. Coagulation factors such as factors IX, 
X and XI; Prothrombin levels, Protein C activation pathway and Antithrombin 
levels and functionality.  
During this study it has been very difficult to get hold of samples from ICU on 
a regular basis. Looking into how to improve the supply of samples from ICU 
would be very beneficial for this investigation. 
Further studies on the effects of extensive use of Hepzyme on any heparin 
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